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Περὶ δὲ τῆς ἀπορίας τῆς εἰρηµένης περί τε τοὺς ὁρισµοὺς καὶ περὶ τοὺς ἀριθµούς͵ τί 
αἴτιον τοῦ ἓν εἶναι; πάντων γὰρ ὅσα πλείω µέρη ἔχει καὶ µὴ ἔστιν οἷον σωρὸς τὸ πᾶν 
ἀλλ΄ ἔστι τι τὸ ὅλον παρὰ τὰ µόρια͵ ἔστι τι αἴτιον. 
 
With respect both to definitions and to numbers, what is the cause of their unity? In 
the case of all things which have several parts and in which the totality is not as it 
were a mere heap, the whole is something besides the parts. 
 
        
       Aristotle, Metaphysics 1045a.11 
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Abstract 
The Mycobacterium tuberculosis (Mtb) genome encodes hundreds of proteins with unknown 
or putative function based on sequence similarity to characterised proteins. Incomplete 
knowledge of Mtb functional genomics undermines efforts to understand the complex 
biological repertoire of this deadly human pathogen. While bioinformatics provides useful 
clues about gene function, biochemical characterisation of gene products remains essential 
to accurate annotation, particularly in cases where functional redundancy is suggested based 
on the presence of multiple homologous proteins. The Mtb genome includes 7 genes which 
encode conserved hypothetical proteins with unknown function that are annotated as 
“pyridoxine 5’-phosphate (PNPOx)-like” proteins based on structural similarity: Rv2607, 
Rv2991, Rv1155, Rv2074, Rv3369c, Rv1875, Rv0121c. PNPOx is a flavin mononucleotide 
(FMN)-dependent enzyme involved in the biosynthesis of the crucial cofactor, pyridoxal 5’-
phosphate (PLP). The work presented in this thesis shows that while Rv2607 exhibits 
canonical PNPOx activity, Rv1155 and Rv2991 do not have affinity for FMN as do other 
members of the PNPOx class. They instead bind tightly to the unusual flavin coenzyme F420 
by isothermal calorimetry (ITC), saturation transfer difference (STD) NMR, and X-ray 
crystallography. Although recent studies have drawn attention to F420 due to its role in 
activating the promising anti-tuberculosis drug PA-824, little is known about the function of 
this coenzyme in Mtb metabolism. In order to identify the substrate recognition properties of 
Rv1155 and Rv2991 respectively, a novel application of fragment-based approaches was 
employed. A library of fragments was designed based on known ligands to flavoenzymes and 
screened for binding to Rv1155 and Rv2991 in the presence and absence of F420 using STD 
NMR and differential scanning fluorimetry. Rv1155 and Rv2991 show affinity for distinct 
classes of fragments. Using a computational method known as “virtual fragment linking,” 
fragment binding data was used to predict and test potential substrates. This approach to 
probing structure-function relationships may serve as a generalisable method for exploring 
functional diversity within a structural class of proteins. 
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Chapter 1 
Introduction 
 
1.1 Tuberculosis is a pressing global health problem 
 
Tuberculosis (TB) has afflicted humans for thousands of years. The earliest 
evidence of TB infection was discovered in the preserved remains of a mother 
and child who lived in the Eastern Mediterranean approximately 9000 years ago1. 
Today, the global burden of TB is enormous. The causative bacterium, 
Mycobacterium tuberculosis (Mtb), is amongst the most ubiquitous human 
pathogens known, with an estimated one third of the world population carrying 
the bacterium2. For reasons that are poorly understood, only around 5-10% of 
people who are infected with the bacterium develop active disease3. The most 
recent World Health Organization (WHO) Global Tuberculosis Report revealed 
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that in 2011 there were 8.7 million new cases of TB and 1.4 million deaths from 
TB2. One in four deaths amongst HIV-positive individuals is caused by TB4. 
 The current drug regimen for TB treatment is decades old and falls short 
of controlling this global epidemic5. Drug-susceptible TB is currently treated over 
the course of a minimum of 6 months with the use of isoniazid, rifampicin, 
pyrazinamide and ethambutol for the first 2 months, followed by isoniazid and a 
rifampicin treatment for the remaining 4 months5. This treatment regimen is 
problematic primarily because it is too long and often results in patient 
incompliance, which leads to drug-resistant disease6. Further, some first-line TB 
drugs are incompatible with certain treatments for other conditions, such as 
antiretrovirals for HIV7 and some anti-diabetic medications8.  
 
Figure 1.1. Chemical structures of first-line TB drugs. 
 
 The emergence of drug-resistant strains of Mtb is perhaps the most 
significant threat to the control of TB worldwide9. These strains are classified by 
the extent of their drug resistance as either multidrug-resistant TB (MDR-TB) or 
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 3 
extensively drug-resistant TB (XDR-TB). MDR-TB is characterised by resistance 
to one or more of the first-line drugs against TB, including isoniazid and 
rifampicin, which are the most potent drugs to treat TB currently available10. 
XDR-TB is resistant to isoniazid and rifampicin as well as to any of the 
fluoroquinolones (for example, ofloxacin or moxifloxacin) and to at least one of 
three intravenously administered second-line drugs (amikacin, capreomycin or 
kanamycin)11. The mortality rate among XDR-TB patients is around 70%5. 
Recently, patients with TB that is resistant to all known drugs have been 
reported12.  
 The widespread prevalence of Mtb and drug-resistant strains underscores 
the urgent need for new antibiotics to treat TB13. The emergence of this global 
health threat has driven a recent increase in research activity to identify and 
validate new TB drug targets14. Despite renewed interest in developing new TB 
treatments, realisation of this goal has met with difficulty. There are two major 
challenges: 1) understanding biological processes that are vulnerable to 
chemotherapeutic intervention and 2) designing and implementing strategies to 
develop lead compounds that target these processes15.  
 
1.2 Approaches to TB drug discovery 
 
For much of the 20th century, antibiotics were largely discovered from microbial 
natural products16. The first antibiotic agent against TB was streptomycin6, 
isolated from Streptomyces griseus. By the late 1990s, the widespread 
availability of genome sequencing technologies sparked an interest in identifying 
new targets for antibiotic design17. The genome of Mtb was sequenced in 1998 
and gene products were identified primarily based on sequence similarity with 
known proteins18,19.  
 Candidate drug targets were initially selected by identifying genes 
required for the growth and survival of Mtb. ‘Genetic essentiality’ was ascertained 
via a series of experiments20,21 that measured the phenotypic effect of a 
disrupted gene of interest. Potential targets were taken forward if they had no 
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close homologues in humans. Once a target was identified and validated with 
genetic experiments, it was expressed, purified, and screened against large 
compound libraries to identify inhibitors of target activity. This process is referred 
to as the genome-based, ‘rational’ approach to TB drug discovery. Concurrently, 
an alternative approach to TB drug discovery was developed that entails 
screening compound libraries against cultures of Mtb cells. Using this method, a 
hit compound is one effective in killing Mtb cells, as quantified by a minimum 
inhibitory concentration (MIC) value22. Although whole-cell screening has 
produced far more hits with anti-tubercular activity, each approach offers certain 
advantages and limitations, which are described in the following.  
 
1.2.1 Whole cell screening 
 
Whole cell screening (WCS) has been successful in producing hits that 
subsequently can be developed into clinical candidates for TB. Important anti-TB 
compounds derived from active compounds identified by WCS include the 
benzothiazinones (BTZs)23,24, PA-82425, SQ10926, and TMC207 or bedaquiline27 
(trade name Sirturo), which recently became the first drug in four decades to be 
approved by the United States Federal Food and Drug Administration (FDA) for 
the treatment of TB28. 
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Figure 1.2. Chemical structures of anti-TB compounds discovered using WCS. 
 
 WCS is typically conducted in a high-throughput format that monitors the 
effect of the compound on Mtb growth and survival. Compounds can be 
screened against the bacterium in a microplate under a wide variety of 
environmental conditions, including those that mimic various disease states. 
Bacterial viability can be rapidly accessed with the use of spectroscopic 
techniques that detect colorimetric indicator dyes29, ATP levels30,31,32 or 
recombinant GFP levels33. Compounds with low MIC are further investigated to 
determine the effect of dose on cell viability and to rule out non-specific 
cytoxocitiy. The mechanism of action for promising active compounds is 
determined by sequencing the genome of spontaneous drug-resistant 
mutants25,24, affinity purification34, or comparative transcriptional fingerprinting for 
drugs with a known killing mechanism35. This approach often reveals new, 
compound-induced bactericidal mechanisms and targets that are not necessarily 
predictable by genome analysis.  
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 Although WCS screening has been fruitful in identifying compounds that 
inhibit Mtb growth, it also has several limitations and weaknesses. For example, 
growth inhibition can occur by several mechanisms and follow-up investigation of 
hit compounds sometimes reveals that they are generally cytotoxic36. Further, 
target identification for a WCS hit is a lengthy and costly process that can be 
difficult to carry out successfully in practice, particularly if drug-resistant mutant 
strains prove to be particularly challenging to isolate37. Optimisation of a WCS-
derived hit without knowledge of its target is an inefficient process that precludes 
hypothesis-driven analysis of structure-activity relationships. By contrast, target-
based screening and rational drug design, discussed in the following section, can 
rapidly advance a hit to a lead compound. Although WCS offers the advantage of 
identifying targets vulnerable to inhibition, subsequent efforts to optimise lead 
compounds are hampered by a lack of information about the target. 
 
1.2.2 Target-based screening and rational drug design 
 
At the turn of the 21st century, the availability of technology to facilitate high-
throughput crystallography changed the landscape of drug design and heralded 
the era of rational, structure-based drug design38. It was thought that three-
dimensional structures of proteins would bridge the gap between genomic 
information and medical breakthroughs39. Target-based drug design generally 
involves screening compound libraries against the target protein using 
biophysical or enzymatic assays. X-ray crystal structures of the hit compounds in 
complex with the target protein are then obtained and used to design new 
compounds with enhanced potency40. Several structural genomics initiatives 
were established in the last decade to encourage rational drug design efforts. 
The Tuberculosis Structural Genomics Consortium (TB-SGC) has produced over 
250 unique open reading frame structures since its inception in 200041. One 
advantage of rational drug design programmes for bacterial proteins (over 
eukaryotic proteins) is that they are often readily expressed using recombinant 
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systems and can be purified in large quantities required for crystallisation and 
screening experiments17; however, there are many ways in which bacterial 
systems are challenging for lead compound development, as described in 
section 1.2.3. Rational drug design was particularly emphasised in the early 
phases of TB drug discovery and although it has been relatively unsuccessful in 
producing lead compounds, it still plays an important role today’s TB drug design 
efforts. 
 
1.2.2.1 High-throughput screening for rational drug design 
 
Target-based high-throughput screening (HTS) involves screening a purified 
macromolecule against large libraries containing on the order of 104-106 
compounds. HTS typically includes assays that measure either in vitro protein 
activity or binding affinity22,37. Many HTS programmes are initiated with a priori 
knowledge of the target structure. ‘Hit’ compounds, i.e. those that meet the 
imposed standards for activity inhibition or binding, are co-crystallised with the 
target to elucidate the binding mode.  
 In vitro protein activity assays monitor rates of product formation in the 
presence and absence of a test compound by a spectrophotometric technique. 
For compounds that inhibit the protein activity relative to the control, half the 
maximal inhibitory concentration (IC50) is typically measured, which is obtained 
from a dose-response curve. Inhibitors for a number of TB protein targets have 
been discovered using this approach, including InhA (target of known drug 
isoniazid42), PknA and PknB (essential serine/threonine kinases43,44,45), MenB (an 
enzyme in the menaquinone biosynthetic pathway46), and PanC (pantothenate 
synthetase47).  
 HTS programmes are sometimes conducted with binding assays rather 
than activity assays, although this approach is relatively less common in TB drug 
design efforts. It involves one or more methods that provide rapid, qualitative 
binding results. Compounds binding to the target protein are typically further 
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characterised to determine the binding affinity and binding mode. The techniques 
used to collect such data are described in the following section on fragment-
based approaches to rational drug design. HTS programmes for Mtb isocitrate 
lyase (GlaxoSmithKline and Novarits Institute for Tropical Diseases) and InhA 
(GlaxoSmithKline and Global Alliance for TB Drug Development) have been 
reviewed37, although the results have not been published. In each case, very 
hydrophobic active sites may have selected for compounds with undesirable 
physiochemical properties37. 
 While a number of novel inhibitors of Mtb proteins have been identified by 
target-based HTS, none have emerged as clinical candidates. This is partly due 
to the limitations of genome-based, rational drug design for anti-TB drug design 
in general, as discussed in section 1.2.1.3. However, the HTS approach to 
rational drug design introduces additional challenges to lead compound 
discovery. HTS requires access to large very compound libraries which are costly 
to develop and challenging to maintain48. Although HTS produces more tightly 
binding initial hits, increasing their potency and simultaneously improving their 
biophysical profile can often be difficult49. These challenges can be addressed by 
fragment-based approaches to rational drug design.  
 
1.2.2.2 Fragment-based approaches 
 
Fragment-based drug discovery (FBDD) is gaining traction in the pharmaceutical 
industry as a complementary or alternative approach to HTS. The first fragment-
based drug, Vemurafenib, was approved by the FDA in 2011 for the treatment of 
metastatic melanoma50 and there are several fragment-based drug candidates 
currently in clinical trials51 (please refer to Figure 1.3 for a summary of the 
fragment-based approach that lead to the discovery of Vemurafenib). 
‘Fragments’ are low molecular weight molecules (<300 Da) with low chemical 
complexity that interact weakly, yet specifically, with a macromolecular target52. 
Information about fragment binding modes can be used to link, alter, or grow 
Chapter 1!
 
 9 
bound fragments so as to improve affinity for the target. FBDD can be applied to 
a wide range of targets, including enzymes53,54,55,56,57, nucleic acids58, and 
protein-protein interactions59,60. Fragments have been used to derive lead 
antibiotics against bacterial targets53,54,61,62,63,64,65. The FBDD approach is an 
appealing alternative to HTS technology because enhancing the potency of a 
fragment hit is a stepwise process that allows for the systematic incorporation of 
ligand binding interactions and parallel fine-tuning of its physiochemical 
properties.  
 
Figure 1.3. Summary of the fragment elaboration approach to discover Vemurafenib, the first 
fragment-based drug to be approved by the FDA. Vemurafenib targets oncogenic a B-raf kinase, 
which is implicated in malignant melanoma. (A) The structure of fragment 3-aminophenyl-7-
azaindole shown bound to Pim-1 kinase (IC50 > 200 µM). (B) The structure of an elaborated 
fragment, 3-(3-methoxybenzyl)-7-azaindole, bound to the kinase domain of fibroblast growth factor 
receptor 1 (IC50 ≈ 1.9 µM). (C) The structure of Vemurafenib bound to B-raf kinase (IC50 = 31 nM)66. 
Superimposition of the structures in A and B, revealed that the azaindole scaffold can target the 
hinge region in kinases and that modifying substitution sites on the scaffold can optimize potency 
and selectivity for B-raf kinase67. Screening various substituted compounds against the oncogenic 
B-raf kinase led to the discovery that the difluoro-phenylsulfonamide motif has enhanced selectivity 
for the oncogenic B-raf67.  
The relative weakness of fragment-target interactions requires sensitive 
biophysical methods to detect binding. Techniques such as ligand-observed 
nuclear magnetic resonance (NMR)68, differential scanning fluorimetry (DSF)69, 
high-throughput X-ray protein crystallography70,71, surface plasmon resonance 
(SPR)72, and mass spectrometry (MS)73 are used to screen fragment libraries. 
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These screening technologies have been used in FBDD programmes in various 
combinations and manners, with no two screening programs completely alike. 
There is no “universal” way to conduct a fragment screen, partly because this 
process is dependent on both the nature of the target and the availability of 
screening resources.  
 In our laboratory, we have demonstrated that many targets are tractable 
in FBDD programs using a three-stage process consisting of preliminary 
screening, validation, and characterisation stages, as described in Figure 1.1. 
The preliminary fragment screening is conducted with DSF. The validation phase 
consists of confirming the preliminary screen hits by ligand-observed NMR 
methods. In the final phase, the validated fragments are further characterised by 
approaches, such as isothermal titration calorimetry (ITC) and X-ray 
crystallography. Low throughput, low cost methods are used to screen and 
validate the majority of the fragment library followed by lower-throughput, 
information-rich experiments to characterise relatively few binding fragments in 
detail. Each of these methods is described below.  
 DSF (also known as thermal shift or thermal unfolding) is a spectroscopic 
technique used to measure the temperature-dependent unfolding of a protein. 
This is achieved by monitoring the fluorescence of a dye that preferentially binds 
to hydrophobic protein surfaces exposed upon unfolding74,75,76. The dependence 
of fluorescence on temperature is described by a sigmoidal curve and the 
inflection point of the transition defines the melting temperature of the protein 
(denoted as Tm). A change in Tm in the presence of a ligand is termed the 
“thermal shift” and is used to distinguish binding ligands (ΔTm > 0) from non-
binders (ΔTm ≤ 0)77. A number of experimental parameters must be optimised to 
conduct a fragment screen using DSF. These include dye concentration, protein 
concentration, buffer type and ionic strength, ligand concentration, temperature 
range, and DMSO concentration. A number of dyes are commonly used in 
DSF77, but SYPRO® Orange is preferred for fragment screening due to its high 
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excitation wavelength (500 nm), which reduces the risk of compound 
interference69.  
 
Figure 1.4. Three stage fragment screening cascade for fragment selection. The cascade consists 
of preliminary fragment screening, hit validation, and binding characterisation. Higher throughput 
techniques are used at an early stage of the process, and more complicated lower-throughput 
approaches are used for characterisation.  
 
 NMR spectroscopy is perhaps one of the most trusted fragment screening 
techniques, as it was the first reported tool to screen fragments78 and is 
commonly used today79. Ligand-observed NMR experiments are most widely 
applied to fragment screening because they do not require protein structural 
information and are not restricted by protein size80. Examples of ligand-observed 
NMR techniques include saturation transfer difference (STD)81, water-ligand 
observed by gradient spectroscopy (WaterLOGSY)82, and Carr-Purcell-Meiboom-
Gill (CPMG) sequence83,84.  
 STD involves selective perturbation of protein-specific methyl proton 
resonances (typically 0.5 ppm to 1 ppm), which rapidly diffuses throughout the 
protein81. This results in a transfer of magnetisation from the protein to any 
Stage 1: Preliminary screening 
Stage 2: Validation 
Stage 3: Characterization 
X-ray 
crystallography 
Differential 
scanning 
fluorimetry 
Ligand-
observed NMR 
spectroscopy 
Isothermal 
titration 
calorimetry 
Fragment library 
Candidates for 
elaboration 
~1
0 
fr
ag
m
en
ts
   
   
   
   
30
-5
0 
fr
ag
m
en
ts
   
   
   
~1
00
0 
fr
ag
m
en
ts
 
R
FU
 
Temp (°C) 
Chapter 1!
 
 12 
transiently bound ligands via the nuclear Overhauser effect (NOE)68. If the 
fragment binds to the target protein, the build-up of NOE that is transferred to the 
ligand results in enhanced signal corresponding to the resonances of that ligand 
in the STD spectrum. A number of factors affect the signal strength in an STD 
experiment, including protein size, duration of on resonance irradiation, the 
frequency of irradiation, the dissociation constant of the ligand, the ligand/protein 
ratio, and the field of the spectrometer85. As such, it is useful to vary parameters 
such as ligand and protein concentration, the frequency of irradiation, and the 
duration of irradiation. A control experiment in the absence of protein is 
performed to confirm that the observed change is protein-dependent.  
 In the WaterLOGSY experiment, magnetisation is transferred to the 
ligand from the bulk water, mainly through water molecules bound in or adjacent 
to the ligand binding site86,82. If the fragment is bound, the negative NOEs will 
dominate the signal. No change in the sign of the WaterLOGSY signal indicates 
that the fragment is unbound. CPMG is used to detect fragment binding by 
relying on differences in the relaxation rates of fragment NMR signals between 
the bound and free states87. In the CPMG experiment, a time delay of 100–400 
ms is used before acquisition to filter out the observed signals for rapidly relaxing 
ligands83,84. Small molecules relax slowly giving rise to sharp peaks, while 
proteins relax quickly and tend to show broad NMR signals. Relaxation-edited 
NMR experiments exploit such differences in relaxation properties between 
proteins and small molecules68. A signal decrease is expected in the presence of 
protein if the fragment binds the protein.  
 Fragments that are confirmed to bind to the protein by NMR are typically 
characterised by ITC to obtain thermodynamic information about the binding 
interaction. ITC directly measures the heat associated with forming or breaking 
non-covalent bonds (ΔHobs) and the stoichiometry of binding (n). This information 
can be used to determine the KD. With the equilibrium binding constant and 
ΔH°obs, ΔS° and ΔG° can be calculated using the relationships in the following 
equation. 
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Full thermodynamic characterisation of binding fragments is very useful for 
downstream inhibitor design and optimisation.  
 Fragment-based approaches have been used to discover inhibitors for 
proteins in Mtb, including of pantothenate synthetase (PtS)88,89 (best KD = 
860 nM), the protein tyrosine phosphatases PtpA64 and PtpB65 (best Ki =1.4 µM 
for PtpA, Ki = 0.22 µM for PtpB), and cytochrome P45054 (best KD = 28 µM). 
However, thus far no fragment-derived compounds have been reported with a 
low MIC for Mtb. While inactive against wild type Mtb, the aforementioned PtS 
inhibitors were shown to inhibit the growth of conditional mutant strains that 
underexpress pantothenate synthetase90. 
 
1.2.2.3 Shortcomings of rational drug design  
 
Genome-derived, target-based antibiotic design efforts have failed to produce 
clinical candidates to date17. Inhibitors developed by rational methods have been 
ineffective in measurably reducing Mtb growth and survival. A problem may be 
that some inhibitors fail to reach their target either because they cannot penetrate 
the thick mycobacterial cell wall36 or because of efflux mechanisms91. There is 
insufficient understanding of the physiochemical basis for cell-permeability. Even 
if the inhibitor overcomes the hurdle of cell entry, bactericidal mechanisms may 
be too slow. For example, rationally-designed, potent inhibitors of Mtb peptide 
deformylase were taken up by cells92, but the kinetics of growth inhibition were so 
slow that only moderate efficacy was observed in mouse models36,36. 
 Another potential pitfall for target-based inhibitor design efforts is the 
effect of compensatory metabolic mechanisms. While a potent inhibitor can 
effectively inhibit one enzyme in a metabolic pathway, alternative pathways can 
circumvent the metabolic effects of this inhibition. For example, nicotinamide 
adenine dinucleotide (NAD) salvage pathways in Mtb can compensate for 
inhibition of the de novo NAD biosynthetic pathway93, which is essential for Mtb 
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survival and was thought to be a good drug target94. Some compensatory 
metabolic pathways can be difficult to predict from the Mtb genome, particularly 
because about one third of the Mtb genome encodes proteins of unknown or 
putative function19.  
 
1.2.3 WCS and rational design as complementary approaches  
 
WCS and target-based approaches were previously conducted in isolation, which 
limited TB drug discovery efforts by their respective weaknesses. While WCS is 
an effective method of identifying targets in Mtb vulnerable to chemical 
intervention, there is no efficient way to enhance the potency of a WCS hit. 
Rational, target-based approaches can rapidly drive up the potency of hit 
compounds. New strategies aim to integrate these two approaches to efficiently 
arrive at lead compounds36. WCS and genome sequencing is used to identify 
target and discover active, cell-permeable chemical scaffolds, while rational 
methods are applied to enhance the binding affinity and introduce favourable 
physiochemical properties. Protein structural information bridges the gap 
between these two phases. The process is summarised in a schematic shown in 
Figure 1.2.  
Figure 1.5. A new strategy for TB drug design. The schematic represents the workflow for 
combined WCS (left) and for target-based screening (right). WCS is applied to identify active, cell-
permeable compounds and a target vulnerable to inhibition. Bioinformatic analysis can be used as 
a starting point for generating hypotheses about the function of the target. The target must be 
cloned into an expression vector, expressed, and purified for basic biochemical characterisation. A 
protocol for protein purification is developed on a scale that is appropriate for crystallisation trials 
and screening experiments. Screening is conducted via ligand-binding or enzyme assays. Hits and 
leads are developed and potency is increased based on protein structural information. The figure is 
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adapted from Terstappen, G.C. et al. Nat. Rev. Drug Discov. 2007.34 
 
This new approach for TB drug discovery is currently being applied to the BTZ 
series of compounds, which target DprE1, a decaprenylphosphoryl 
arabinofuranose24. DprE1 was identified by whole genome sequencing of BTZ-
resistant mutants24, it was functionally characterised95, and crystal structures of 
DprE1 complexed with active compounds were recently reported96,97. This 
structural information serves as foundation for future inhibitor design studies. 
Central to this approach is identifying and characterising the protein target, a task 
which is often non-trivial, as there is a serious dearth of functional genetic 
information for Mtb. This challenge to TB drug discovery is further discussed in 
the following section, as well as in Chapter 5. 
 
1.3 Functional annotation of the Mtb genome 
 
The whole genome sequencing of H37Rv18, a laboratory reference strain, was an 
important advance in the understanding of Mtb biology. However, at the time of 
its release, only 40% of H37Rv gene products could be putatively annotated with 
computational methods that assign function based on sequence similarity to 
proteins in other organisms. Four years after the sequence of the H37Rv genome 
was published, it was re-annotated using updated genomic and functional data 
for sequence comparisons, which identified new coding sequences and adjusted 
predicted protein lengths19. This study found that of the 3995 predicted proteins, 
2052 could be annotated with a putative function (51%), although only around 
150 of these proteins were characterised experimentally. Further, 272 proteins 
were annotated as “proteins with unknown function” without homologues in other 
organisms. A staggering 1051 proteins were annotated as ‘conserved 
hypothetical proteins’ (CHPs), which are proteins with homologues in multiple 
phylogenetic lineages, none of which have a known function. An online public 
database, TubercuList98 (http://tuberculist.epfl.ch/), provides current and curated 
information on the H37Rv genome that is revised as experimental studies yield 
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new functional information. The Mtb proteome includes 1032 CHPs98 today, 
despite intensive efforts to close this knowledge gap.  
 
1.4 A novel application of fragment-based methods for natural substrate 
prediction 
 
A major objective of this doctoral work is to develop an experimental approach to 
rapidly generate and test hypotheses of CHP function in Mtb using high-
throughput biophysical screening technologies. The ‘biological function’ of a 
protein can be difficult to define, as there are several means of describing the 
functional properties of proteins. Herein, CHP function is defined in terms of its 
molecular recognition properties, which can reveal important information about 
substrate specificity. ‘Molecular recognition’ describes chemical phenomena 
guided by specific, non-covalent interactions99. Molecular recognition between 
proteins and small molecules in the cell is crucial to many important biological 
processes100, and it is therefore key to understanding protein function. 
 This thesis aims to explore the applicability of fragment-based 
approaches (described in Section 1.2.2.2) to interrogate CHP function, rather 
than to discover drug-like molecules. Fragments may be effective chemical tools 
to investigate enzyme substrate specificity. They are able to make efficient, ‘high-
quality’ binding interactions because they contribute significantly to favourable 
binding energy, even though they are weak binders by virtue of their size101. It 
has been shown that fragment-enzyme interactions can recapitulate the binding 
of natural substrates102. Fragments can identify the ‘hot spots’ of a protein, which 
contribute most to the binding energy of a ‘fragmented’ natural ligand103. Further, 
fragments have been discovered that mimic structural features of natural 
ligands88,104. This approach is further described in Chapter 5. 
 This novel application of fragment-based methods, along with structural 
and enzymatic approaches, is applied to a family of enzymes annotated in the 
Chapter 1!
 
 17 
Mtb genome as pyridoxine 5’-phosphate oxidase (PNPOx)-like proteins with 
unknown function. This thesis describes the characterisation of three enzymes 
within this class: Rv2607, Rv1155, and Rv2991. Bioinformatic studies of PNPOx-
like proteins are described in Chapter 2. This analysis led to the hypothesis that 
Rv2607 is a true PNPOx, while Rv1155 and Rv2991 are structurally-related to, 
but functionally distinct from, other known PNPOxs. Biophysical and enzymatic 
characterisation of Rv2607 is described in Chapter 3 and that of Rv1155 and 
Rv2991 is discussed in Chapter 4. Chapter 5 describes work done to date to 
screen Rv1155 and Rv2991 with a targeted fragment library to identify reactions 
catalysed by these enzymes. 
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Chapter 2 
Analysis of pyridoxine 5’-phosphate oxidase-like 
proteins in M. tuberculosis using sequence- and 
structure-based comparisons 
 
2.1 Background 
 
The Mtb genome encodes a class of related CHPs annotated as pyridoxine 5’-
phosphate oxidase (PNPOx)-like proteins with unknown function. This class 
includes Rv2607, Rv1155, Rv2991, Rv2074, Rv0121c, Rv1875, and Rv3369. 
They belong to superfamily cl00381 in the National Center for Biotechnology 
Information (NCBI) Conserved Domain Database (CDD). This superfamily is 
composed of hundreds of PNPOxs and other flavin mononucleotide (FMN) 
binding proteins. The seven Mtb proteins are related to each other by a shared 
domain called ‘pyridoxine 5’-phosphate oxidase domain’ (PF01243), as 
determined by the Pfam algorithm105. Although PLP is essential for Mtb growth 
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and virulence in vivo106, the PNPOx-like proteins are non-essential for Mtb 
survival according to Himar1-based transposon mutagenesis experiments in 
H37Rv21,105. 
 In organisms as disparate as E. coli and H. sapiens, there is only one 
gene for PNPOx106,107. It is an FMN-dependent enzyme encoded by the gene 
pdxH that oxidises either pyridoxine 5’-phosphate (1), a primary alcohol, or 
pyridoxamine 5’-phosphate (3), a primary amine, into pyridoxal 5’-phosphate 
(2)108 (Figure 2.1). Pyridoxal 5’-phosphate (PLP), the active form of vitamin B6, is 
one of the most ubiquitous and versatile cofactors in the cell109. For detailed 
information about this reaction and its relation to other biosynthetic pathways, 
please refer to Chapter 3, Figure 3.1.  
 
 
Figure 2.1. Schematic of PNPOx-catalysed PLP formation. PNPOx catalyses the production of 
PLP, the bioactive form of vitamin B6. PNPOx is capable of oxidising either a primary amine or a 
primary alcohol to an aldehyde in the presence of its cofactor, FMN. Molecular oxygen is the 
terminal electron acceptor of this reaction. 
 
 Although this enzyme catalyses the same reaction in both E. coli and in 
humans, it serves a different metabolic function in each organism. In E. coli, 
PNPOx participates in de novo PLP biosynthesis108. Humans lack the 
biosynthetic machinery to produce PLP de novo and PNPOx therefore functions 
to salvage PLP107. There are two classes of organisms capable of de novo PLP 
biosynthesis: those that produce PLP via the deoxyxylulose (DXP)-dependent 
pathway and those that synthesise PLP via the DXP-independent pathway110. In 
the DXP-dependent pathway, PNPOx directly participates in PLP formation by 
catalysing the final step of the PLP biosynthesis111. Few organisms have the 
DXP-dependent pathway, including E. coli and some γ-proteobacteria. The 
majority of PLP-synthesising organisms (most bacteria, archaea, fungi, and 
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plants) use the DXP-independent pathway, in which PLP is synthesised by a 
single multienzyme complex called PLP synthase112. More in-depth information 
on DXP-dependent and independent pathways is provided in Chapter 3 (Figure 
3.1). Organisms that synthesise PLP via PLP synthase are thought to use 
PNPOx for PLP salvage. However, bioinformatic analysis described in this thesis 
shows that some PLP-biosynthesising organisms with genes encoding PLP 
synthase lack genes for PNPOx (Table 2.1). This observation suggests that in 
organisms with the DXP-independent pathway, PNPOx is not required to 
maintain adequate PLP levels in the cell. 
 The genome of Mtb includes homologues of PLP synthase and PNPOx. 
However, the Mtb genome is unusual amongst organisms using the DXP-
independent pathway because it has seven genes encoding copies of PNPOx 
homologues. Because PNPOx activity is not required for PLP production in 
organisms expressing PLP synthase, the number of PNPOx homologues in Mtb 
is particularly surprising and unexpected. This suggests that these PNPOx-like 
proteins in Mtb may serve diverse, yet unknown functions not related to PLP 
metabolism. This chapter describes efforts to generate hypotheses on alternate 
functions of PNPOx-like proteins in Mtb by mining available genomic, proteomic, 
and structural information. 
2.2 Analysis of PNPOx-like proteins using comparative genomics 
 
2.2.1. Protein sequence alignments 
 
The NCBI protein basic local alignment sequence tool (BLASTp) was used to 
search for homologues of the Mtb pfam01243 PNPOx-like proteins in other 
organisms. Mycobacterium smegmatis, a close relative of Mtb, encodes 
homologues to all of the PNPOx-like proteins found in Mtb, except Rv3369 
(Table 2.1). These proteins are found in other mycobacteria, including M. 
ulcerans, M. avium, and M. gilvum. The vastly reduced genome of M. leprae, 
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which is incapable of surviving outside of the host organism, encodes 
homologues of Rv1155 and Rv2607 only113. Another PLP-synthesising organism, 
Streptomyces coelicolor, has homologues of four of the seven Mtb PNPOx-like 
proteins. These homologues are annotated as PNPOx-like CHPs with unknown 
function in the genomes examined. 
 
Mtb M. smegmatis %  ID M. leprae %  ID S. coelicolor %  ID 
Rv2607 MSMEG_5675 69 ML2131 67 SCO4387 44 
Rv1155 MSMEG_5170 80 ML1508 88 SCO5312 57 
Rv2991 MSMEG_0048 73 ─  SCO1357 38 
Rv2074 MSMEG_3880 85 ─  SCO0838 53 
Rv0121c MSMEG_6526 59 ─  ─  
Rv1875 MSMEG_6576 35 ─  ─  
Rv3369 ─  ─  ─  
Table 2.1. Summary of NCBI gene product annotations for PNPOx-like proteins in selected 
organisms where PNPOx activity is considered to play a role in PLP salvage. Homologues were 
assigned using BLASTp114 for sequence alignments with E-values less than 10-6. Percent identities 
(% ID) between the Mtb PNPOx-like genes and their respective homologues in M. smegmatis, 
M. leprae, and S. coelicolor are shown to the right of the gene annotation. Percent identity has 
been calculated by dividing the number of identical residues by the length of the alignment using 
pBLAST ALIGN (www.blast.ncbi.nih.gov). 
 
 Sequence alignments of PNPOx-like proteins in Mtb reveal relatively low 
sequence similarity within the group (Table 2.2). Among the PNPOx-like family 
members that share significant sequence similarity (a pair having an E value of 
less than 1e-05), the sequence identity is around 30%. There is no statistically-
significant sequence similarity between Rv2607 and any of the other PNPOx-like 
proteins.  
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Table 2.2. Pairwise percent identities of PNPOx-like proteins. Percent identity has been calculated 
by dividing the number of identical residues by the length of the alignment using pBLAST ALIGN 
(www.blast.ncbi.nih.gov). Where the percent identity is replaced by a dash, the E value was too 
high to align the two sequences (E value > 1e-05). 
 
2.2.2 Gene clusters and gene synteny analysis 
 
Gene clusters and gene synteny were analysed for clues on PNPOx-like protein 
function. A gene cluster is a set of genes that encodes proteins that participate in 
the production of the same, similar, or related products115. Gene clusters are 
created by gene duplication and divergence. The duplicated genes evolve and 
acquire new but related function, and maintain physical proximity on the 
chromosome115. Comparative gene synteny, as applied here, is an approach to 
generating hypotheses about gene function, which stipulates that two or more 
gene clusters may have derived from a single, ancestral genomic region that is 
present in other organisms. Evolutionarily-related organisms have similar blocks 
of genes, perhaps in similar relative locations in the genome116.  
 The genetic regions surrounding PNPOx-like genes were examined in 
Mtb and M. smegmatis. Schematics of each gene region in Mtb and the 
analogous region in M. smegmatis are shown in Figure 2.2. Gene rv2607 is 
upstream of rv2606c and rv2604c, homologues of PLP biosynthetic genes, pdx1 
and pdx2 (Figure 2.2A). Pdx1 and Pdx2 (twelve molecules of each) associate to 
form the PLP synthase complex. The spatial proximity of rv2607 to pdx1/pdx2 in 
the Mtb genome suggests that Rv2607 may be involved in PLP metabolism.  
Rv2607 Rv1155 Rv2991 Rv2074 Rv0121c Rv1875 Rv3369 
Rv2607 100 – – – – – – 
Rv1155 – 100 33 24 31 30 27 
Rv2991 – 33 100 24 28 – – 
Rv2074 – 24 24 100 – – – 
Rv0121c – 31 28 – 100 – – 
Rv1875 – 30 – – – 100 – 
Rv3369 – 27 – – – – 100 
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Figure 2.2. Gene cluster comparisons of PNPOx-like proteins in Mtb and M. smegmatis. In each 
panel, genes are coloured according to their function: PNPOx-like proteins in Mtb and homologues 
in M. smegmatis (red), intermediary metabolism (yellow), lipid metabolism (orange), information 
pathways (cyan), RNA (brown), regulation (grey), PE/PPE family of proteins (purple), membrane 
proteins (green), and unknown proteins (black). Gene region information was obtained from the 
databases TubercuList98 v2.6 (http://tuberculist.epfl.ch/index.html) and SmegaList v1.0 
(http://mycobrowser.epfl.ch/smegmalist.html). Gene regions surrounding Mtb PNPOx-like proteins 
Rv2607 (A), Rv1155 (B), Rv2991 (C), Rv2074 (D), and Rv0121c (E) and the respective 
homologues in the genome of M. smegmatis. In the Mtb genome, the gene encoding Rv2607 is 
adjacent to pdx1 and pdx2, proteins that form the PLP synthase. Other annotated gene products 
near the PNPOx-like genes include: tesB2 (acyl-CoA thioesterase II), pimA (alpha-
mannosyltransferase), gltA (citrate synthase), leuC/D (3-isopropylmalate dehydratase), gluU 
(tRNA-glutamate), glnU (tRNA-glutamine), gltS (glutamyl-tRNA synthase), cobK (precorrin-6X 
reductase), cobM (precorrin-3 methylase), cobL (precorrin-6Y C(5,15)-methyltransferase), oxcA 
(oxalyl-CoA decarboxylase), fadD7 (fatty-acid-CoA ligase), and pepA (serine protease). 
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M. smegmatis homologues of pdx1 (MSMEG_2937), pdx2 (MSMEG_2939), and 
rv2607 (MSMEG_5675) are not found in the same position in the genome, 
relative to the Mtb proteins. In both the genomes of Mtb and M. smegmatis, the 
gene encoding Rv2074 is upstream of a series of enzymes involved in cobalamin 
biosynthesis (cobK, cobM, and cobL). The gene regions surrounding Rv1155, 
Rv2991, and Rv0121c in Mtb or M. smegmatis do not provide much useful 
information, as many are also CHPs or proteins of unknown function. 
2.3 Structural analysis of PNPOx-like proteins 
 
X-ray structures of unliganded Rv2607117, Rv2991, Rv1155118, and Rv2074119 
have been reported. Each protein structure was annotated as a PNPOx-like 
protein with unknown function in the Protein Databank (PDB). The structures of 
the canonical PNPOxs of E. coli120 and human121 in complex with their ligands, 
PLP and FMN, have been crystallised and determined to 1.8 Å and 2.0 Å 
resolution, respectively. PNPOx proteins consist of two domains: a large and a 
small domain (Figure 2.3). The large domain consists of an anti-parallel beta 
barrel with Greek key topology, capped on each end by an alpha helix. The small 
domain is primarily alpha helical. Each protein varies in architecture of the alpha 
helices that comprise the small domain. In E.coli and human PNPOx, the small 
domain forms the PLP binding site, while the large domain binds FMN. The 
biologically-active form of PNPOx is the homodimer108.  
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Figure 2.3. Structural superimposition of E. coli PNPOx and Mtb PNPOx-like proteins (protomers). 
The alignment was performed using the MultiProt Server (http://bioinfo3d.cs.tau.ac.il/MultiProt/) 
with the E. coli PNPOx107 (cyan; PDB ID: 1G77), Rv2607117 (red; PDB ID: 2A2J), Rv1155118(green; 
PDB ID: 1W9A), Rv2991 (yellow; PDB ID: 1RFE), and Rv2074119 (purple; PDB ID: 2ASF). The 
image was rendered using Chimera122. 
 
PNPOx-like proteins Rv1155, Rv2074, Rv2991, and Rv2607 share common 
structural elements. Superimposing all PNPOx-like proteins yields a low C-alpha 
root-mean-square deviation (RMSD) of 1.43 – 1.71 Å (number of residues: 
Rv1155, 140; Rv2074, 124; Rv2991, 153; Rv2607, 202). The coordinates of each 
of these proteins were compared with those of all other structures deposited in 
the PDB using the distance alignment matrix method (Dali)123(Table 2.2). This 
technique is the three-dimensional equivalent of a sequence alignment. The 
algorithm uses a sum-of-pairs method to compare intramolecular distances123. 
The top result structure shown in Table 2.2 (second column) has the lowest 
RMSD and best Z score relative to the query molecule (first column) among all 
other structures deposited in the PDB. 
One clear structural difference among the proteins in question is that Rv1155, 
Rv2991, and Rv2074 contain a similar small domain, while those of Rv2607 (red) 
and the E. coli PNPOx (cyan) are better aligned. This difference is also reflected 
in the Dali results. Structurally, it appears that Rv1155, Rv2991, and Rv2074 are 
more similar to each other than they are to either Rv2607 or the E. coli PNPOx. 
 


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Table 2.3. Summary of Dali results for PNPOx-like proteins Rv2607 (PDB ID: 2A2J), Rv1155 (PDB 
ID: 1W9A), Rv2991 (PDB ID: 1RFE), and Rv2074 (PDB ID: 2ASF). The top Dali result has the 
lowest backbone RMSD relative to the query molecule of all structures deposited in the PDB. The Z 
score above 2 indicates that the structures have significant structural similarities. All results were 
obtained using the Dali Server DaliLite123 v.3 (http://ekhidna.biocenter.helsinki.fi/dali_server/start). 
 
There is high sequence similarity amongst PNPOxs across many organisms, 
particularly in the region of the protein that forms the binding site at the dimer 
interface. Five sequence motifs are conserved in PNPOxs of various 
species: -RIVLLK- (residues 67-72 in E. coli), -SRKA- (residues 87-90), -QS- 
(146-147), -EFWQG- (residues 189-193), and -RLHDR- (residues 197-201). 
Figure 2.4 A shows sequence alignment of two known PNPOxs (E. coli and 
human) and the Mtb PNPOx-like proteins. In Figure 2.4, the conserved 
sequences are coloured and correspond to the residues shown in the structure of 
E. coli PNPOx, which demonstrates that these motifs are situated around the 
PLP and FMN binding sites. Of the Mtb PNPOx-like proteins, only Rv2607 
shares the canonical PNPOx sequence motifs; all other PNPOx-like proteins in 
Mtb lack these conserved sequences. 
Mtb PNPOx Top Dali result RMSD (Å) No. residues Z score % ID 
Rv2607 E. coli PNPOx 1.3 199 25.0 41 
Rv1155 Rv2074 2.6 125 13.0 24 
Rv2991 Rv2074 
B. subtillis BH0577 
1.9 
1.9 
125 
126 
15.0 
15.8 
24 
19 
Rv2074 Rv2991 1.9 160 15.0 24 
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Figure 2.4. Sequence alignment of E. coli PNPOx, H. sapiens PNPOx, and Mtb PNPOx-like 
proteins. (A) Sequence alignment of E. coli PNPOx, human PNPOx, and PNPOx-like proteins from 
Mtb (Rv2607, Rv1155, Rv2991, Rv2074, Rv1875, Rv3369, and Rv0121c) with highlighted PNPOx 
sequence motifs. (B) Surface representation of E. coli PNPOx (PDB ID: 1G77) bound to PLP and 
FMN (C atoms, grey) with residues comprising conserved PNPOx sequence motifs represented as 
spheres: -RIVLLK- (red), -SRKA- (green), -QS- (yellow), -EFWQG- (purple), -RLHDR- (cyan). The 
alignment was performed with TCoffee124 (http://tcoffee.crg.cat/apps/tcoffee/do:regular) and the 
structure was created with molecular graphics software, CCP4mg125. 
 
E.coli TAMVVATVDEHGQPYQRIVLLKHYDEKG---------------MVFYTNLGSRKAHQIENNPRVSLLFPW---------- 105
Human NAMCLATCTRDGKPSARMLLLKGFGKDG---------------FRFFTNFESRKGKELDSNPFASLVFYW---------- 133
Rv2607 NAMVLATVA-DGKPVTRSVLCKILDESG---------------VAFFTSYTSAKGEQLAVTPYASATFPW---------- 114
Rv1155 SIGVLATIKHDGRPQLSNVQYHF-DPRKLL-------I------QVSIAEPRAKTRNLRRDPRASILVDA-DDGW---SY 79
Rv2991 RTGTLATIGPDGQPHLTAMWYAV-IDGE---------------IWLETKAKSQKAVNLRRDPRVSFLLED-GDTYDTLRG 86
Rv2074 HLAMLTTLRADNSPHVVAVGFTF-DPKTHI-------A------RVITTGGSQKAVNADRSGLAVLSQV---DGA---RW 81
Rv1875 GLAVVSTVRADGTVQASLVNVGL-LPHPVSGE----------PSLGFTTYGKVKLGNLRARPQLAVTFR---NGW---QW 78
Rv3369 LYGWLTTVARSGQPVPRLVWFYF-DGTD---------------LTVYSMPQAAKVAHITAHPQVSLNLDS---------- 78
Rv0121c PVARLATSTPDGTPHLVPVVFAL-GARRPAEATGADVIYTAVDAKRKTTQRLRRLANLEHNPRASVLVDSYADDWTQLWW 92
E.coli HTLERQVMVIGKAERLSTLEVMKYFHSRPRDSQIGAWVSKQSSRISARGILESKFLE----LKQKFQ---QGE-VPL-PS 176
Human EPLNRQVRVEGPVKKLPEEEAECYFHSRPKSSQIGAVVSHQSSVIPDREYLRKKNEE----LEQLYQ---DQE-VPK-PK 204
Rv2607 YQLGRQAHVQGPVSKVSTEEIFTYWSMRPRGAQLGAWASQQSRPVGSRAQLDNQLAE----VTRRFAD--QDQ-IPV-PP 186
Rv1155 AVAEGTAQLTPPA-----AAP--DDDTV--------------------EALIALYRN----IAGEHSDWDDYR-QAMVTD 127
Rv2991 VSFEGVAEIVEEP------EA------LH----------R------V--G-VSVWER----YTGPYTDECKPMVDQM-MN 130
Rv2074 LSLEGRAAVNSDI------DA------V----------RD--------AELRYAQR---------------YR-TPRPNP 115
Rv1875 ATVEGRAQLVGPD------DP------RPW-------LVDG-------ERLRLLLREVFTAAGGTHDDWDEYD-RVMAQE 131
Rv3369 DGNGAGIIVVGGTAAVVATDVDCRDDAPY----------------------WAKYRE----DAAKFGL--TEA-IAA-YS 128
Rv0121c VRADGVAAIHRDG------EV------M--------------------R---AAYRL----LRAKYAQ--YQS-VPL-NG 129
E.coli FWGGFRVSLEQIEFWQGGEHRLHDRFLYQR---------------ENDAWKIDRLAP 218
Human SWGGYVLYPQVMEFWQGQTNRLHDRIVFRRGLPTGDSPLGPMTHRGEEDWLYERLAP 261
Rv2607 GWGGYRIAPEIVEFWQGRENRMHNRIRVAN---------------G----RLERLQP 224
Rv1155 RRVLLT--LPISHVYGLPP-----GM------------------------------R 147
Rv2991 KRVGVRIVARRTRSWDHRKLGLPHMSVGG------------------------STAP 163
Rv2074 RRVVIE--VQIERVLGSAD-----LLDR----------------------------A 137
Rv1875 QRAVVL--ITPTRIYSN---------------------------------------G 147
Rv3369 TR--LK--ITPTRVWTTPT-------------------------------------G 144
Rv0121c P--VIA--IAVQRWA-SWH-------------------------------------A 144


Chapter 2!
 
 28 
 A detailed analysis of the residues that form the binding pocket of each 
PNPOx-like protein in Mtb is crucial for formulating hypotheses about enzymatic 
activity. Figure 2.5 shows the E. coli PNPOx active site with bound PLP and 
FMN120. The FMN is engaged in a hydrogen-bonding network, making 
interactions with residues Arg 67 (A), Ile 68 (A), Leu 70 (A), Tyr 82 (A), Thr 83 
(A), Arg 88 (B), Lys 89 (B), Gln 111 (B), Gln 146 (B), Ser 147 (B), Arg 201 (B). 
The PLP also makes extensive contacts with both the protein monomers. 
Stacking interactions between the PLP and FMN stabilise the binding of both 
ligands. 
 
 
Figure 2.5. Structure of the E. coli PNPOx active site. The substrate is PLP (C atoms, blue) and 
FMN is in grey (PDB ID: 1G77)108. Hydrogen bonds are represented as dashed black lines. 
Residues from a second protomer are denoted with an apostrophe. The active site is formed at the 
dimer interface. The image was created using CCP4mg125. 
 
The respective active sites of Rv2607, Rv2074, Rv2991, and Rv1155 are 
found in the small domain, as predicted by CASTp126, a server that identifies 
structural pockets and cavities on protein surfaces (http://sts-
fw.bioengr.uic.edu/castp/). The E. coli PNPOx exhibits similar domain 
arrangement (Figure 2.3), with a validated active site situated in corresponding 
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position. Figure 2.6 shows structural alignments of the E. coli PNPOx with 
Rv2607 (A), Rv2074 (B), Rv2991 (C), and Rv1155 (D), respectively. All 
structures of the Mtb PNPOx-like proteins are unliganded, while the E. coli 
PNPOx structure includes both PLP and FMN in the active site. Residues in the 
E. coli protein that interact with PLP and FMN have been compared to spatially 
analogous residues in the Mtb PNPOx-like proteins. Polar contacts were 
analysed between the ligands (PLP and FMN) and any surrounding atoms, 
excluding the solvent and including both the E. coli and Mtb proteins. Residues in 
analogous positions relative to PLP or FMN in the E. coli and Mtb proteins are 
defined as having a ‘conserved interaction’ with that ligand. 
 Overall, the Rv2607 binding site structure is very similar to that of the 
E. coli PNPOx. Almost all the ligand-protein interactions seen in the E. coli 
PNPOx are conserved in Rv2607 (Figure 2.6A). There is also a high degree of 
residue type conservation, with some exception in the residues that form 
backbone interactions with the FMN, e.g. Ser77 and Phe91 in Rv2607. Pédelacq 
et al. report observing some density in the FMN binding site of Rv2607, but could 
not definitively place the cofactor117. It appears that Rv2607 is an unliganded 
PNPOx structure, as Gln155 and Ser 156 (E. coli Gln146 and Ser147) are 
disengaged from interaction with the phosphate moiety of FMN and Tyr138 
(E. coli PNPOx Tyr129) assumes a conformation that prevents it from forming a 
hydrogen bond with the phosphate of PLP (Figure 2.6 A). 
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Figure 2.6. Structural superimpositions of E. coli PNPOx active site with predicted active sites in 
Mtb PNPOx-like proteins. Structural alignment of E. coli PNPOx, cyan, PDB ID: 1G77, and (A) 
Rv2607, red, PDB ID: 2A2J; (B) Rv2074, purple, PDB ID: 2ASF; (C) Rv2991, yellow, PDB ID: 
1RFE; (D) Rv1155, green, PDB ID: 1W9A. Labelled residues correspond to the E. coli PNPOx 
structure unless otherwise noted. Residues shown in each structure are 4.0 Å away from PLP (C 
atoms, blue) and FMN (C atoms, grey). PLP and FMN shown are in the E. coli PNPOx structure 
active site only. The images were rendered using CCP4mg125. 
 
 The structural overlays of E. coli PNPOx with Rv2704 (Figure 2.6B), 
Rv2991 (Figure 2.6 C) and Rv1155 (Figure 2.6 D) reveal that there is little 
evidence that PLP binding could take place in the Mtb proteins. In Rv2074, only 
one of the five residues involved in the PLP-PNPOx interaction is conserved: 
Tyr104 (Tyr82 in E. coli PNPOx). In Rv2991, no residues interacting with PLP in 
E. coli PNPOx are conserved. Only one residue, Gln37, seems to be spatially 
positioned within the Rv1155 active site to interact with PLP.  
 Some structural evidence suggests that Rv2074, Rv2991, and Rv1155 
could interact with their predicted cofactor, FMN. A structural superimposition of 
Rv2074 and the E. coli PNPOx reveals that Rv2074 lacks many of the residues 
that interact with FMN in the E. coli protein. However, Lys61 in Rv2074 (Lys89 in 
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E.coli PNPOx) could make interactions with the ribityl moiety of FMN and Thr55 
(Thr83 in E.coli PNPOx) could hydrogen bond to the pyrimidine portion of the 
isoalloxazine ring system of FMN, as the analogous residues do in the E. coli 
PNPOx active site. Further, several main chain interactions with the cofactor are 
conserved in Rv2074. These backbone-FMN interactions are also conserved in 
the predicted Rv2991 active site, along with Lys61 and Thr55, which are 
analogous residues to Lys89 and Thr83 in the E. coli structure. These conserved 
FMN binding interactions are also observed in the Rv1155 active site, which is 
comprised of residues available to engage in main chain interactions with FMN 
(as in Rv2074 and Rv1155). Lys 57 in Rv1155 is found in the analogous position 
as E. coli Lys89, Rv2074 Lys61, and Rv2991 Lys61. Figure 2.7 shows all the 
conserved residues in Rv2074, Rv2991, and Rv1155 that could engage in 
hydrogen bonding interactions with FMN.  
 
Figure 2.7. Residues in Rv2074, Rv2991, and Rv1155 that could engage in hydrogen bonding 
interactions with FMN. Superimposition of conserved residues interacting with FMN in E. coli 
PNPOx (cyan, PDB ID: 1G77), Rv2074 (purple, PDB ID: 2ASF), Rv2991 (yellow, PDB ID: 1RFE), 
and Rv1155 (green, PDB ID: 1W9A). FMN is present in the E. coli PNPOx structure only. Hydrogen 
bonds are represented with dashed lines between FMN and E. coli PNPOx. Conserved residues 
Thr and Lys in Rv2074, Rv2991, and Rv1155 could anchor the ribityl and pyrimidine of FMN, as 
they do in E. coli PNPOx. Several spatially analogous residues in Rv2074, Rv1155, and Rv2991 
that could interact with FMN are not conserved, but the cofactor could make contacts with the main 
chain of each protein, as is seen in the E.coli PNPOx (denoted as ‘MC’). The image was rendered 
using CCP4mg125. 
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Despite that there are few interactions between Rv1155 and PLP, Biswal et 
al. have reported structures of Rv1155 with bound PLP and FMN in separate 
crystals127. The structural overlay of Rv1155-FMN and Rv1155-PLP (Figure 2.8) 
indicates that the binding modes of FMN and PLP in Rv1155 are very different 
with respect to the E. coli PNPOx active site (Figure 2.5). The Rv1155-
FMN/Rv1155-PLP overlay shows that simultaneous binding of FMN and PLP 
seems improbable in Rv1155, as FMN and PLP are clashing and are not 
properly positioned for enzymatic reaction. The E. coli PNPOx binding site, on 
the other hand, is arranged for electron transfer from the substrate to the FMN. 
These findings suggest that the Rv1155-PLP structure may not be reflective of 
the biologically-relevant substrates of Rv1155. Rv1155-FMN may be biologically 
relevant, although FMN in Rv1155 has a different binding mode than it does in 
the E. coli PNPOx and other related proteins. 
 
Figure 2.8. Structural superimposition of Rv1155-FMN and Rv1155-PLP. Rv1155-FMN (PDB ID; 
1Y30) is shown in orange and Rv1155-PLP (PDB ID: 2AQ6) is shown in yellow127. The spatial 
orientation of FMN and PLP in the proposed Rv1155 active site indicates that these ligand-bound 
structures are not biologically relevant. 
 
 Structural analysis of each PNPOx-like protein reveals that the active sites of 
Rv1155, Rv2991, and Rv2074 differ significantly from those of known PNPOxs. 
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Generally, the Mtb PNPOx-like proteins have fewer conserved interactions with 
FMN and PLP. These observations suggest that Rv1155, Rv2991, and Rv2074 
may not bind PLP or FMN at all. Rv2607, however, seems to have the highest 
structural and sequence similarity with the E. coli PNPOx. Rv2607 is also the 
most highly conserved in this protein family across other mycobacterial species, 
including in the reduced genome of M. leprae, and it has the highest homology to 
the PNPOxs of E. coli, Streptomyces coelicolor and Saccharomyces cerevisiae. 
Further, rv2607 is in close proximity to genes encoding PLP synthase in the Mtb 
genome. It is, therefore, the most logical candidate for the canonical PNPOx of 
Mtb. The PNPOx activity of Rv2607 is further explored in Chapter 3. 
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Chapter 3 
Biophysical and enzymatic characterisation of 
Rv2607 as a pyridoxine 5’-phosphate oxidase  
 
3.1 Background 
 
The term ‘vitamin B6’ collectively refers to pyridoxine 5’-phosphate (PNP) (1), 
pyridoxal 5’-phosphate (PLP) (2), pyridoxamine 5’-phosphate (PMP) (3), and 
their respective non-phosphorylated forms128. The bioactive form of vitamin B6, 
PLP, acts as a cofactor to over 140 known enzymatic reactions referenced in the 
Enzyme Commission (http://www.chem.qmul.ac.uk/iubmb/enzyme/), which 
corresponds to about 4% of all classified enzymatic activities. It has been 
described as one of the most versatile cofactors in nature, as it participates in 
transamination, decarboxylation, racemisation, Cα-Cβ bond cleavage, and α,β-
elimination reactions109.  
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 A number of enzymes involved in vitamin B6 metabolic pathways in Mtb 
remain uncharacterised, despite the important role this vitamin plays in the 
cellular metabolism of this pathogen. PLP biosynthesis is required for Mtb 
survival and virulence in vivo and it is a predicted cofactor for a number of 
enzymes essential to Mtb growth106. Therefore, vitamin B6 biosynthesis and 
salvage may be attractive target pathways for the development of novel 
compounds with anti-TB activity. 
 In both prokaryotic and eukaryotic organisms, PNPOx is an FMN-
dependent enzyme encoded by the gene pdxH that produces PLP by oxidising 
either PNP or PMP108. In E. coli and some γ-proteobacteria, PNPOx participates 
in the deoxyxyulose 5’-phosphate (DXP)-dependent PLP biosynthetic pathway111. 
The DXP-dependent pathway consists of 7 enzymes: GapA, PdxB, PdxF, PdxA, 
DXPS, PdxJ and PNPOx (Figure 3.1, left). Together, PdxA and PdxJ catalyse the 
formation of PNP (1) from DXP and 1-hydroxy-3-aminopropane phosphate. 
E. coli PNPOx then oxidises PNP into the bioactive product, PLP. PNPOx in E. 
coli can also recognise PMP as a substrate, although this reaction is not part of 
the de novo PLP biosynthetic pathway and is a vitamin B6 salvage reaction. 
 Most prokaryotes and plants biosynthesise PLP via an alternative route 
called the DXP-independent pathway112 (Figure 3.1, right). The DXP-independent 
pathway includes PLP synthase, a macromolecular complex consisting of 
enzymes encoded by the genes pdx1 and pdx2110. This complex is capable of 
carrying out de novo PLP biosynthesis directly. Pdx2 is a glutaminase, which 
produces ammonia by hydrolysing glutamine, and Pdx1 is a synthase, which 
condenses ammonia, ribulose 5-phosphate, and glyceraldehyde-3-phosphate. 
X-ray crystal structures of PLP synthase129,130 reveal twelve Pdx1 units are 
arranged in two hexameric rings to which twelve Pdx2 subunits attach. The 
complex is described as having a ‘cogwheel-like’ configuration, in which Pdx1 
forms the core of the wheel and the individual Pdx2 units are the cogs110. PLP 
synthase has been identified as a possible drug target for malaria131,132.  
Chapter 3!
 
 36 
 The Mtb genome encodes homologues of proteins involved in the DXP-
independent PLP biosynthetic pathway, pdx1 (Rv2606c) and pdx2 (Rv2604c), 
but lacks the genes for enzymes in the DXP-dependent pathway18 (please refer 
to Chapter 2, Figure 2.2 A for a schematic of the region surrounding Rv2607 in 
the Mtb genome). It has been demonstrated that Mtb synthesises PLP via the 
DXP-independent pathway using PLP synthase and that disruption of the pdx1 
gene generates a vitamin B6 auxotrophic Mtb mutant106. Organisms with genes 
that encode both PLP synthase and PNPOx probably only use the oxidase to 
salvage PLP after it participates as a cofactor in enzymatic reactions107. It is 
unclear whether Mtb can acquire PLP or other forms of vitamin B6 from the 
host106. 
 Of the seven PNPOx-like proteins in Mtb, Rv2607 is the most logical 
candidate for the canonical PNPOx (please refer to Chapter 2 for a detailed 
analysis). Rv2607 has highest sequence similarity to known PNPOxs (Table 2.1). 
The predicted active site of Rv2607 is similar to that of PNPOx homologues in 
other organisms (Figure 2.6 A). Residues known to be important for PLP binding 
in the E. coli and human PNPOx are nearly all conserved in Rv2607 (Figure 2.4 
A). FMN could not be definitively placed in the Mtb PNPOx active site because 
the electron density for the FMN cofactor is weak in the Rv2607 crystal structure. 
However, residues known to interact with FMN in the E. coli and human PNPOx 
enzymes are conserved in Rv2607. Gene expression for rv2607 has been 
detected in over 300 different experimental conditions in vitro133 
(www.tbdb.org/expressionHistory.shtml) as well as in macrophages134. 
Expression of this gene is upregulated by stresses such as exposure of Mtb to 
certain inhibitors of translation and by nitroimidazoles, such as PA-824133.  
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Figure 3.1. PNPOx-catalysed PLP formation in DXP-dependent and DXP-independent PLP 
biosynthetic pathways. In E. coli, PNPOx catalyses the last step in the DXP-dependent PLP 
biosynthetic pathway111. Most organisms capable of PLP biosynthesis produce PLP via PLP 
synthase, a macromolecular complex consisting of Pdx1 and Pdx2110. Organisms with genes that 
encode both PLP synthase and PNPOx likely use PNPOx to salvage PLP from PNP and PMP107, 
which are produced by enzymes that use PLP as a cofactor. These two distinct PLP biosynthetic 
pathways have not yet been found to coexist in the same organism135. 
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3.2 Protein expression and purification of Rv2607 
 
 Rv2607 was obtained as an aminoterminal 6x-histidine (His6x) tag fusion 
construct. A one-step nickel affinity purification procedure was employed to 
isolate Rv2607 and it was freshly purified before each assay. The proper folding 
of Rv2607 was demonstrated using circular dichroism (CD) spectroscopy. In its 
native state, Rv2607 gives a CD signal that is expected from proteins with mixed 
anti-parallel β-barrel and α-helical secondary structure. This CD signal 
disappears when the protein is denatured with 6 M guanidium hydrochloride for 
3 hrs at 25 °C.  
 SDS-PAGE analysis showed that the protein was purified to >95% 
homogeneity and the yield of the purified protein was 140 mg per liter of cells, as 
determined using the Bradford test136, calibrated using bovine serum albumin 
(BSA) standards. Two major protein bands were observed by SDS-PAGE, one 
corresponding to the Rv2607 monomer (~27.5 kDa) and the other corresponding 
to a homodimer (~55 kDa). The dimeric form of the protein appeared to be stable 
under reducing and denaturing conditions in SDS-PAGE (3% β-mercaptoethanol, 
0.1 % SDS). To confirm the identity of the band corresponding to 55 kDa, it was 
analysed by MS, which is described in the following section. 
 
3.3 Analysis of Rv2607 using mass spectrometry 
 
Purified Rv2607 was bright yellow in colour, suggesting the presence of a co-
purified cofactor. The yellow cofactor bound tightly to Rv2607 as purified and was 
unambiguously identified as FMN (m/z 457.2 Da) by nanoflow electrospray 
ionisation mass spectrometry (nESI-MS) after it was isolated from the heat-
denatured protein (Figure 3.2). 
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Figure 3.2. Identification of cofactor bound to Rv2607 by nESI-MS. Cofactor was extracted from 
Rv2607 by heat denaturation, followed by filtration with a 10K Da molecular weight (MW) cutoff 
filter. FMN has a molecular weight of 456.2 Da. (A) Mass spectrum of commercial standard of 
FMN. (B) Mass spectrum of cofactor isolated from heat-denatured Rv2607. 
 
 The intact Rv2607-FMN complex was analysed by nESI-MS, which 
revealed it exists in a predominantly dimeric oligomerisation state (Figure 3.3), 
which is consistent with other known PNPOxs108. Although two FMN binding sites 
exist at the homodimer interface of Rv2607, only one FMN molecule per dimer 
was present in the protein as purified (Figure 3.3). A 2:1 ratio of PNPOx protomer 
to FMN has been reported for other PNPOxs137,138,139.  
 In order to investigate the stability of the dimer, the charge state +14 of 
Rv2607 was isolated in a tandem MS experiment (MS/MS) and submitted to 
collision-induced dissociation (CID). The MS/MS spectrum (Figure 3.4) shows 
that dissociation begins to occur at accelerating voltages of 150 V (trap) and 
110 V (transfer). High accelerating voltages were required to induce dissociation 
of this very stable Rv2607 homodimer. Small populations of both monomers are 
visible at high and low m/z respectively and several additional peaks in the 
spectrum indicate that such high voltages also cause fragmentation of the 
protein, which has been previously reported for a different system140. This result 
is consistent with reducing SDS-PAGE analysis of the protein, which reveals a 
stable dimer. The crystal structure of Rv2607 indicates that the two protomers 
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are very tightly wrapped around each other, as the dimer interface consists of 
about 20% of the total protomer surface117. This work was done in collaboration 
with Dr. Dijana Matak-Vinković (Department of Chemistry, University of 
Cambridge). 
 
 
Figure 3.3. Mass spectrum of intact Rv2607 with co-purified FMN analysed by nESI-MS. The major 
species, C, has peaks with charges ranging from 15+ to 12+ in the 3500-4500 m/z range that 
correspond to a molecular weight of 55376±12. This experimental mass is consistent with the 
calculated mass for the complex of dimeric Rv2607 with one molecule of FMN bound (55442 Da), 
which is derived from the amino acid sequence of the 6x-histidine tagged Rv2607 (54986 Da; 
27493 Da per protomer) and the molecular weight of FMN (456 Da). Monomeric tagged Rv2607 
and truncated Rv2607 monomer (missing 10-11 residues), are present in solution and correspond 
to molecular weights of A (27450±52 Da) and B (26215±54 Da) respectively. A minor dimeric 
species comprised of full length and truncated monomer is represented as species D. Higher 
molecular weight oligomers (trimers E and tetramers F with molecular weights of 110.6 and 82.7 
kDa, respectively) are electrospray-induced non-specific association of monomers and dimers. 
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Figure 3.4. MS/MS spectrum of the Rv2607 homodimer. The isolated precursor ion, charge state 
14+ of the dimeric Rv2607 complex was submitted to CID with accelerating voltages 150 V (Trap) 
and 110 V (Transfer). Low populations of charge-state series A and B corresponding to monomers 
with measured masses 27362 Da (monomer, high m/z region) and 27353 Da (low m/z region) 
begins to occur at these high voltages. High accelerating voltages also caused fragmentation of the 
protein, indicated by a few unassigned peaks at the low and high m/z region. 
 
The 55 kDa protein band was unambiguously identified as Rv2607 by isolating 
the protein by gel filtration and subjecting it to proteolytic digestion. The digested 
fragments were analysed by liquid chromatography (LC) and MS/MS, assigned 
amino acid sequence, and queried with the SEQUEST algorithm141. This analysis 
indicates that the proteolysed fragments belong to the parent molecule, Rv2607. 
 
3.4 Kinetic studies of Rv2607 
 
3.4.1 LC-MS assay to detect Rv2607-catalysed PLP formation 
 
Rv2607-mediated catalysis of PLP formation was examined by LC-MS 
(Figure 3.5). To resolve the product, PLP, from the substrates, PNP and PMP, 
PLP was derivatised with 2,4-dinitrophenylhydrazine (DNPH) to form a PLP-DNP 
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hydrazine. It has been previously reported that PLP readily forms a stable 
hydrazone with phenylhydrazine142. DNPH reactivity with PLP, PNP, and PMP 
was tested (refer to Chapter 6, Figure 6.1 for these control reactions). DNP 
hydrazones are not formed with either PNP or PMP because they lack a reactive 
aldehyde.  
 
Figure 3.5. Reverse-phase HPLC analysis of the PNPOx activity of Rv2607. (A) HPLC 
chromatograms (270 nm) of reaction mixtures containing PNP (i-iv) or PMP (v-viii), FMN, and 
Rv2607, and the associated control reactions. All reactions were carried out in 25 mM potassium 
phosphate buffer (pH 7.8), incubated at 25 °C for 3 hrs, and quenched with DNPH (0.7 mM final 
concentration). Where present, the reaction components were at the following concentrations: 
1 mM PNP or PMP, 10 µM FMN, and 10 µM Rv2607. Reaction mixtures contained: (i) PNP, FMN, 
and Rv2607, (ii) PNP and FMN (enzyme negative control), (iii) PNP and Rv2607 (no added FMN), 
(iv) FMN and Rv2607 (substrate negative control), (v) PMP, FMN, and Rv2607, (vi) PMP and FMN 
(enzyme negative control), (vii) PMP and Rv2607 (no added FMN), (viii) FMN and Rv2607 
(substrate negative control). The peak to the right of PLP-DNPH is DNPH, which has a retention 
time of 8.6 min. (B) Schematic representing assay to identify Rv2607-catalysed PLP formation with 
DNPH derivitisation. 
 
 A peak corresponding to the chemically-synthesised PLP-DNP hydrazone 
(retention time = 7.60 min) was detected in the enzymatic reaction of Rv2607 
with PNP. Electrospray ionisation in the positive mode confirmed it to be the DNP 
hydrazone of PLP (m/z = 428). No such peak was observed in the enzyme and 
substrate (PNP) negative controls, however, a peak was observed in the 
absence of added FMN since the enzyme co-purified with FMN. The PLP-DNP 
hydrazone was not detected when PMP was tested as a substrate (Figure 3.5). 
To eliminate the possibility that the PLP formation observed was due to the 
presence of contaminating endogenous E.coli PNPOx, E.coli Bl21(DE3) cell 
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lysates were tested for PNPOx activity and it was shown that PLP can only be 
detected when Rv2607 is overexpressed. PNPOx activity assays were also 
performed using an inactive PNPOx-like His6x-tagged protein expressed and 
purified in the same manner as was Rv2607. No PLP production was detected. 
These observations confirm that the observed PNP turnover is solely due to 
Rv2607. Further, E. coli PNPOx demonstrates PMP turnover108, while Rv2607 
does not. 
 
3.4.2 Enzymatic reaction time course using 1H NMR spectroscopy 
 
Rv2607-catalysed formation of PLP was observed directly by 1H NMR 
spectroscopy in the presence of Rv2607 and PNP over time (Figure 3.6). 
Increasing signals corresponding to the C2-1H and the aldehyde proton of PLP 
were observed with time with a concurrent decrease in signal from the C2-1H of 
PNP. Under these experimental conditions, there was 75% conversion of the 
substrate after 18 hours. Spiking the reaction mixture with a synthetic standard of 
PLP confirmed that the observed chemical shifts in the reaction mixture 
correspond to PLP (Figure 3.6).  
 
Figure 3.6. 1H NMR analysis of the conversion of PNP into PLP with time. The enzymatic reaction 
(1 mM PNP, 28 µM enzyme, 10% D2O in 25 mM potassium phosphate buffer, pH 7.8) was 
incubated for 18 hrs at 25 °C in the spectrometer. Left; stacked 1H NMR spectra recorded at 
various time points and after the addition of authentic PLP. The starred peak corresponds to PLP 
hydrate. Right; a plot of percent substrate conversion versus time. Substrate conversion was 
determined by comparing integrals of the C2-1H signals associated with PLP (7.80 ppm) to that of 
PNP (7.75 ppm). 
 
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3.4.3 Michaelis-Menten kinetics for Rv2607 and PNP 
 
 Rv2607-catalysed PNP oxidation exhibited Michaelis-Menten kinetics with 
a kcat and KM of 0.01 s‑1 and 360 µM respectively (Figure 3.7). The reported kcat 
and KM for the E. coli enzyme108 and PNP are 0.2-0.8 s‑1 and 2 µM, respectively 
and the kcat and KM for the human enzyme121 with PNP are 0.19 s‑1 and 1.8 µM, 
respectively. While both the E. coli and human PNPOx recognize PMP as a 
substrate, significant PLP formation was not seen when PMP was tested as a 
substrate for Rv2607. To our knowledge, Rv2607 is the first example of a PNPOx 
that does not oxidise PMP to PLP. The biological implication of the kinetic 
differences between Rv2607 and other PNPOxs is not yet known. It may be that 
Rv2607 exhibits a relatively low catalytic efficiency because it is not directly 
involved in the biosynthesis of PLP (as is the E. coli PNPOx) and unlike the 
human PNPOx, it is operating in a cellular environment which possesses the 
machinery for de novo PLP biosynthesis. 
 
 
Figure 3.7. Michaelis-Menten plot for Rv2607 with PNP as a substrate. The rate of PLP formation 
was monitored spectrophotometrically (λmax = 388 nm, ε = 4900 cm-1M-1) for various concentrations 
of PNP. All solutions were made in 100 mM potassium phosphate buffer, pH 7.8. 
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3.5 Proposed mechanism 
 
 The mechanism of PNP oxidation has not been determined with certainty, 
although it has been proposed that direct hydride transfer may occur from C4’ of 
the substrate to N5 of FMN107. This would result in resonance stabilisation of the 
oxidised product. We propose that for Rv2607, a hydride is transferred from PNP 
to FMN and oxidised FMN is regenerated with molecular oxygen. 
 
 
Figure 3.8. A schematic of the proposed mechanism for the oxidation of PNP by Rv2607. A 
hydride from the substrate, PNP, is transferred to FMN bound to Rv2607. In the Rv2607 active site, 
His209 could act as a base to deprotonate PNP and Glu59 could act as an acidic group to 
protonate N1 of FMN. The oxidised cofactor is regenerated in the presence of molecular oxygen.  
 
3.6 Conclusions 
 
Although the Mtb protein encoded by Rv2607 was annotated as a member of the 
PNPOx family based on sequence alignment, biochemical data to support this 
classification had not been previously reported. PNPOx isolated from prokaryotic 
and eukaryotic sources (pig137 and sheep138 brain, recombinant human121, 
recombinant E. coli143 and rabbit liver144) are reported to catalyse the oxidation of 
PNP as well as PMP to form PLP. Rv2607 catalyses the oxidation of PNP, but 
not PMP, in the presence of FMN, which makes it unique within this family of 
enzymes. 
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Chapter 4 
Identification of Rv2991 and Rv1155 as novel F420 
binding proteins 
 
4.1 Introduction 
 
Rv2991 and Rv1155 are annotated in the Mtb genome as CHPs that are 
structurally related to the PLP-producing enzyme PNPOx. Bioinformatic analysis 
indicates that they may be dependent on flavin cofactor FMN (please refer to 
Chapter 2 for further details). This thesis chapter investigates the cofactor 
preference of Rv1155 and Rv2991 using biophysical techniques and provides 
evidence that Rv2991 and Rv1155 do not bind FMN, as predicted, but instead 
bind to an unusual flavin found in mycobacteria called F420. 
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4.1.1 F420-dependent activation of PA-824, a TB drug currently in clinical trials 
 
Current drug design efforts target biological features that exist in Mtb, but that do 
not exist in human cells. For example, isoniazid145 and ethambutol146 are first-line 
TB drugs that target metabolic pathways unique to mycobacteria. They inhibit 
proteins involved in the biosynthesis of the mycolic acids, which comprise part of 
the unique mycobacterial cell wall. This strategy is thought to be effective 
because it decreases the likelihood of off-target effects in the patient. 
 Currently in clinical trials is a promising TB candidate drug, PA-824, that 
requires activation by the mycobacterial nitroreductase Ddn (gene name: 
rv3547)25,147. Ddn is dependent on the flavin coenzyme F420 (7,8-didesmethyl-8-
hydroxy 5-deazaflavin), which is prevalent in mycobacteria, but is relatively rare 
in nature and absent in humans. Ddn facilitates hydride transfer from the reduced 
coenzyme, F420H2, to PA-824, resulting in the release of nitrous oxide, which is 
quickly converted to nitric oxide (NO) in the cell (Figure 4.1)147. It has been 
demonstrated that this intracellular release of reactive nitrogen intermediates 
(RNI) leads to cell death by inhibiting multiple enzyme and nucleic acid targets 
within Mtb148. PA-824 is effective for persistent, latent, active, and drug resistant 
infections. Interestingly, it is well documented that RNI are used as a natural 
defense system by activated host macrophages against Mtb149. Therefore, 
PA-824 is the first antibiotic that functions by mimicking the chemical defence 
strategies of innate immunity150. The effect of PA-824-mediated RNI release on 
Mtb viability is magnified in part because Ddn-F420, a unique mycobacterial 
enzyme-coenzyme system, is required for denitration.  
4.1.2 F420 is a low redox potential flavin coenzyme and obligate hydride donor 
 
Coenzyme F420 was first observed in mycobacteria in the early 1960s151,152 
although it was not chemically identified until 1972 when it was isolated from 
methanogenic Archaea153. It is now known that F420 and its precursor FO are 
present in a variety of organisms across several phylogenetic linages, including 
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archaea, bacteria and eukaryotes. F420 is named after its intense absorbance at 
420 nm, which is dependent on the reduction-oxidation (redox) state of the 
molecule. 
 
Figure 4.1 A comparison of the nitroimidazole mechanism of action and the NO release that occurs 
as a result of the innate immune response. In aerobic conditions, which favour replicative bacteria, 
the host cell can produce RNI via the inducible nitric oxide synthase (iNOS); however, iNOS activity 
is significantly reduced in anaerobic conditions (which favours latent, persistent Mtb). 
Nitroimidazoles are capable of producing NO and other RNI in both aerobic and anaerobic 
conditions. Figure adapted from Nathan, C. Science. 2008150.  
 
 
 F420 shares some structural similarities to more common flavins, such as 
riboflavin, FMN and flavin adenine dinucleotide (FAD) (Figure 4.2). These include 
the isoalloxazine ring core, ribityl moiety, and phosphate. However, the tricyclic 
ring system in F420 differs from that in FMN and FAD in the following respects: 1) 
F420 lacks the central nitrogen at position 5 found in other common flavins, which 
is replaced by a carbon atom. For this reason, the F420 ring system is referred to 
as a deazaisolloxazine ring system, and it reactivity is restricted to hydride 
transfer at this site154. 2) F420 has a hydroxyl group at the C8 position, while 
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riboflavin, FMN, and FAD are methylated at C7 and C8. Extending beyond the 
phosphate moiety, F420 has a lactyl group and polyglutamate tail with γ-glutamyl 
linkages. In Mtb, most F420 molecules have a polyglutamate tail that is five to six 
glutamate residues in length155. 
Although coenzyme F420 and other common flavins are structurally 
similar, they differ significantly in their redox properties. For example, F420 is an 
obligate hydride donor, while FMN, FAD, and riboflavin can participate in one and 
two-electron redox reactions145,156. In this sense, F420 is more similar to the 
conventional hydride carrier, NAD(P)+. However, F420 has a lower midpoint 
potential for hydride transfer (-380 mV) than NAD(P)+ (-320 mV)146,157. It has 
been suggested that the low reduction potential of F420 may play a role in the 
non-replicating persistence of Mtb, as F420 could facilitate redox reactions in 
anaerobic environments25,157. It is also thought that F420-dependent enzymes may 
be involved in protection against oxidative stress and nitrosative 
damage147,158,147,159,148,160. This is consistent with evidence which shows Mtb 
mutant stains defective in F420 biosynthesis are hypersensitive to RNI148,149. 
 
Figure 4.2. Structures of F420, flavins, and NADP+ and their associated chemical reduction 
potentials150,157,150,161.  
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 F420-catalysed enzymatic reactions have been studied in a range of 
microbes, but particularly in methanogens, where they play an integral role in 
carbon fixation reactions. Enzymes Mer and Mtd use coenzyme F420 to catalyse 
the reduction of N5, N10-methylene-tetrahydromethanopterin (methylene-H4MPT) 
and methenyl-H4-tetrahydromethanopterin (methenyl-H4MPT) respectively in the 
reduction of carbon dioxide to methane162,163. It has also been demonstrated that 
deazaflavin-dependent oxidoreductases in Streptomyces participate in the 
biosynthesis of antibiotics tetracycline164 and tomaymycin165, for which the 
coenzyme facilitates the enzymatic redox transformations of ketones and imines, 
respectively. F420-dependent enzymes have been shown to catalyse aromatic 
nitro reduction in the degradation of picric acid and 2,4-dinitrophenol166. F420 has 
been implicated in the degradation of mycotoxins in Mycobacterium smegmatis, 
which involves the reduction of carbon–carbon double bonds167.  
 
4.1.3 F420-dependent enzymes in Mtb 
 
Little is known about the enzymes in Mtb that require F420 as a coenzyme and the 
reactions they catalyse. One that has been well studied in Mtb and related 
mycobacteria is the F420-dependent glucose 6-phosphate dehydrogenase 
(FGD)168,152,169,153,170. The Mtb genome encodes two FGDs (fgd1, fgd2). This 
enzyme catalyses the oxidation of glucose 6-phosphate, producing reduced 
F420H2, which is required for PA-824 activation. Interestingly, the Mtb genome 
encodes two glucose 6-phosphate dehydrogenases that are dependent on 
NADPH as well.  
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Figure 4.3. Predicted F420-binding enzymes in Mtb using phylogenetic profiling. There are 28 
predicted F420-dependent enzymes, 7 of which belong to the DDN class, 14 to the LLM class, and 
7 to the PNPOx class. This figure was created based on the computational study from Selengut et 
al. J. Bacteriol. 201026. 
 
 With the exception of FGD and Ddn, no other F420-dependent proteins in 
Mtb have been experimentally identified and characterised in Mtb. A recent 
comparative genomics study suggests that there are at least 28 unique F420-
binding enzymes in Mtb that fall into three classes: the deazaflavin-dependent 
nitroreductase (DDN), the luciferase-like monooxygenase (LLM), and the PNPOx 
families, which all include homologues in other organisms that are known to bind 
either FMN or FAD154,171 (Figure 4.3). The family members are related to one 
another by global fold similarity. These enzymes were linked with F420 
metabolism in part by identifying orthologues in multiple species that contain F420 
biosynthetic genes. Conserved residues important to F420 binding were identified 
in each enzyme class155,171.  
4.2 Objective and approach 
 
The aim of this work is to identify and characterise the cofactor dependence of 
predicted flavoproteins Rv1155 and Rv2991. There are two facets to this 
objective: 1) to demonstrate a cofactor-protein binding interaction 2) to observe 
cofactor-mediated enzyme catalysis. The cofactor preference of Rv1155 and 
Rv2991 was investigated using biophysical techniques, which is described in 
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Section 4.4 of this chapter. Test enzymatic reactions for Rv1155 and Rv2991 are 
reported in Section 4.5. 
4.3 Expression and purification of Rv1155 and Rv2991 
 
Rv1155 was best expressed as a maltose binding protein (MBP)-His6x fusion 
protein. Other fusion constructs of Rv1155 tested for expression in BL21(DE3) 
E.coli cells included glutathione S-transferase (GST) and His6x tags. The 
Rv1155-His6x fusion protein was insoluble. While the GST-Rv1155 fusion protein 
expressed soluble protein, the yield was about 7 mg per 1 L of cell culture, which 
was half the yield for His6x-MBP-Rv1155. Rv2991 was expressed and purified as 
a His6x fusion protein. The MBP-His6x and His6x tags were efficiently cleaved from 
the Rv1155 and Rv2991 gene products respectively with tobacco etch virus 
(TEV) protease. After a 2 hr incubation at room temperature (25 °C), 95% 
cleavage of each protein was observed with a molar ratio of 1:100 TEV to fusion 
protein. The tag, uncleaved fusion protein, and TEV-His6x were removed from the 
reaction mixture with a second nickel affinity column. Each protein was further 
purified by gel filtration and stored in 100 mM Tris-HCl, pH 7.5, 50 mM NaCl. The 
final protein solution was >95% pure as assessed by SDS-PAGE. The mass of 
untagged Rv1155 was determined to be 16227.0 Da by MS, which is the 
calculated molecular weight of Rv1155 without the first methionine and with an 
added glycine. The mass of Rv2991 is 18034.0 Da by MS, which corresponds to 
the molecular weight of Rv2991 without the first methionine or the terminal 
proline and with an added glycine at the N-terminus. Unlike Rv2607, recombinant 
Rv1155 and Rv2991 isolated from E. coli cells were colourless proteins and there 
was no evidence to suggest that either Rv1155 or Rv2991 co-purified with a 
small molecule. 
 
4.4 Purification of F420  
 
F420 is not available commercially available and must be isolated from an 
organism with the biosynthetic machinery to produce the coenzyme. 
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M. smegmatis cell cultures have been previously used for F420 purification172 and 
a recent protocol was developed to increase F420 production by transforming M. 
smegmatis cells with an overexpression vector containing fbiA, fbiB, and fbiC173, 
genes involved in F420 biosynthesis. M. smegmatis cells transformed with the 
vector containing fbiABC have higher F420 production levels (~5.5x) than do WT 
cells under the conditions tested (See Chapter 6, Figure 6.2). The method for 
F420 purification described in this thesis was developed by modifying and 
optimising existing methods172,173 and is described in detail in Chapter 6, section 
6.5. From 800 g M. smegmatis +fbiABC cells, 102 mg pure F420 was obtained. 
 
4.5 Evidence for Rv1155-F420 and Rv2991-F420 binding interactions 
 
4.5.1 Rv1155 and Rv2991 bind to F420 as determined by biophysical methods 
 
 A crystal structure of Rv1155 bound to FMN has been determined127; 
however, there is disagreement over the binding affinity of FMN to Rv1155127,118. 
Although Rv2991 is annotated as a probable FMN-dependent protein in the Mtb 
genome, no experimental binding data has been published to confirm the 
Rv2991-FMN binding interaction. A series of redox cofactors were assessed for 
binding using DSF, including FMN, flavin adenine dinucleotide (FAD), and 
nicotinamide adenine dinucleotide phosphate (NADPH), and F420 (Figure 4.4). 
Both Rv1155 and Rv2991 show a strong preference for F420. A significant thermal 
shift was observed for each protein in the presence of F420. With the addition of 
F420 (50 µM), the Tm of Rv1155 was increased by 5.3 ± 0.4 °C, while that of 
Rv2991 was increased by 6.4 ± 0.4 °C. The Tm of either Rv1155 or Rv2991 was 
not significantly increased in the presence of FMN, FAD, or NADPH (Figure 4.4 
C). Some stabilisation in the Tm of Rv2991 was observed with FMN 
(2.2 ± 0.4 °C), but a binding interaction between FMN and Rv2991 could not be 
detected by ITC. Further, Rv2991, unlike FMN-dependent Rv2607, does not co-
purify with FMN when expressed recombinantly in E. coli cells. 
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Figure 4.4. Cofactor recognition of Rv1155 and Rv2991 assessed by DSF. (A) Melting curves of 
Rv1155 (left) in the presence (red) and absence (blue) of F420 and the associated negative 
derivatives with respect to temperature (right). (B) Melting curves of Rv2991 (left) in the presence 
(orange) and absence (green) of F420 and the associated negative derivatives with respect to 
temperature (right). (C) Table of Tm values for Rv1155 and Rv2991 in the presence of F420, FMN, 
FAD, or NADPH. The change in Tm  in the presence of a test cofactor (ΔTm) is relative to the 
cofactor negative control. Fluorescence measurements (λex: 587 nm, λem: 607 nm) were made 
over a temperature range of 30 - 80°C. All Rv1155 samples (100 µL total volume) contained the 
following: 100 mM Tris-HCl pH 8.0, 100 mM NaCl, 2.5x SYPRO® Orange, and 5 µM Rv1155, 
with or without 50 µM cofactor. All Rv2991 samples (100 µL total volume) contained the 
following: 20 mM potassium phosphate buffer pH 7.4, 20 mM NaCl, 20 mM DTT, 1x SYPRO® 
Orange, and 5 µM Rv2991, with or without 50 µM cofactor. 
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 Preliminary DSF trials with apoenzyme Rv2991 revealed very high 
baseline signal, i.e. high fluorescence at temperatures lower than the Tm. This 
high initial fluorescence can be indicative of protein aggregation or denaturation. 
The presence of Rv2991 aggregates was later confirmed by dynamic light 
scattering (DLS). Extensive DSF buffer optimisation studies were carried out to 
eliminate the aggregates (discussed in Chapter 6). Buffer conditions that 
produced the lowest initial fluorescence contained 20 mM dithiothreitol (DTT), 
which prevents cross-linking via exposed cysteines on the Rv2991 surface (2 
cysteines per Rv2991 protomer). The baseline DSF signal for Rv2991 is lower in 
the presence of F420, but not with other cofactors tested. Some remaining initial 
fluorescence may be attributed to aggregation caused by an unstructured 
carboxyterminal ‘tail’ in Rv2991 comprised of 14 residues. In order to investigate 
the contribution of this unstructured region to aggregation, a mutant of Rv2991 
was created that lacks the final 14 residues at C-terminus of Rv2991 
(-KLGLPHMSVGGSTA-). This truncated mutant was unstable and precipitated 
upon isolation, indicating that the unstructured tail is important to Rv2991 
stability.  
 F420 binding to Rv1155 and Rv2991 was confirmed by STD NMR.(Figure 
4.5). The observed aromatic resonances of the deazaisoalloxazine protons are 
consistent with those reported in the literature155 and are clearly seen in the 
difference spectra for both the Rv1155- and Rv2991-containing samples. 
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Figure 4.5. F420 binds to Rv1155 and Rv2991 by STD NMR. The aromatic region of the 1D 1H 
NMR spectrum for F420 (top) includes signals due to protons in the deazaisoalloxazine ring system 
(top right). The STD NMR spectra indicate that F420 is binding in both Rv1155 and Rv2991. Each 
sample contains 25 µM Rv1155 or Rv2991 (or the equivalent volume of buffer for the protein 
negative control) and 500 µM F420 in 100 mM potassium phosphate buffer, pH 7.8, 50 mM NaCl, 
10% D2O. The STD signal was not observed in the absence of protein. 
 
 The Rv2991-F420 and Rv1155-F420 binding interactions were further 
characterised by ITC (Figure 4.6). The KDs for F420 binding to each enzyme are in 
the low micromolar range, which is consistent with the reported binding constants 
for other F420-dependent proteins170,169,174. ITC also indicates that Rv1155 and 
Rv2991 each bind F420 in a 1:1 molar ratio. This observation is confirmed for 
each enzyme-coenzyme complex by nESI-MS, which showed that Rv1155 and 
Rv2991 predominantly exist as homodimers that bind two molecules of F420 
(Figure 4.7). One dominant species is observed by nESI-MS for Rv2991-F420, 
which is a homodimer bound to two molecules of F420-6, a F420 species with six 
glutamates (Figure 4.7 A). The spectrum also reveals that a relatively smaller 
proportion of sample is unliganded monomer. The mass spectrum for Rv1155-
F420 reveals a heterogeneous population of enzyme-coenzyme complexes, with 
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evidence for dimeric Rv1155 binding one or two molecules of F420-5 (F420 with 
five glutamates), one or two molecules of F420-6, both F420-5 and F420-6, and no 
F420 (apoenzyme). The most prevalent species in this mixture, however, was 
homodimeric Rv1155 bound to two molecules of F420-6. Differences in the mass 
spectra for Rv2991 and Rv1155 could be attributed to the molar ratio of protein to 
F420 present in each sample (1:5 for Rv2991 and 1:1 for Rv1155). This is further 
discussed in the following on X-ray crystallographic studies with Rv1155 and 
Rv2991. 
 
 
Figure 4.6. ITC binding isotherms for F420 titrated into Rv1155 and Rv2991. A solution of (A) F420 
(275 µM) was injected into Rv1155 (10 µM), and (B) F420 (1150 µM) was injected into Rv2991 (85.5 
µM). The ligand and protein were dialysed into the same buffer, 100 mM potassium phosphate, pH 
7.4, 20 mM NaCl. The enthalpy change for each injection as a function of the molar ratio of total 
injected F420 to Rv1155 (A) or Rv2991 (B) is shown (lower panel, squares). A one-site binding 
model fitting was used to the KD for Rv1155 (3 µM) or Rv2991 (4 µM). 
A B 
Chapter 4!
 
 58 
 
Figure 4.7. Nano-ESI mass spectra of intact Rv2991 and Rv1155 in the presence of F420. (A) 
Mass spectrum of Rv2991. The spectrum clearly shows the predominant species has peaks with 
charges ranging from +13 to +10 in the 2800-4000 m/z range that correspond to a MW of 
38782 ± 23 Da. This experimental mass is consistent with the calculated mass for the complex of 
dimeric Rv2991 with two molecules of F420-6 bound (38644 Da), which is derived from the amino 
acid sequence of Rv2991 excluding the aminoterminal methionine and the carboxyterminal 
proline and including one additional glycine residue retained from the TEV cleavage (36064 Da; 
18032 Da per protomer) and the MW of F420-6 (1290 Da). A minor species in the sample is 
unliganded monomeric Rv2991, corresponding to a mass of 18032 Da. The concentration of 
Rv2991 used to generate the spectrum is 12 µM, in the presence of 5x molar excess of F420. (B) 
Mass spectrum of Rv1155. The sample is heterogeneous, with a mixture of dimeric Rv1155 
bound to one or two molecules of F420-5 or F420-6. Unliganded dimeric Rv1155 also exists in this 
mixture. The calculated mass of dimeric Rv1155 excluding the aminoterminal methionine and 
including an added glycine is 32453 Da, which is consistent with the MW of species F 
(apoenzyme Rv1155). The MW of F420-5 is 1159 Da. The concentration of Rv1155 used to 
generate the spectrum is 10 µM with approximately 1:1 molar ratio of Rv1155 to F420. 
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 The biophysical data presented here unambiguously demonstrate that 
F420 binds to both Rv1155 and Rv2991. Rv1155 and Rv2991 should therefore be 
annotated as F420-dependent enzymes, a classification which deviates from their 
current status in Mtb genome databases as FMN-dependent PNPOx-like 
proteins. 
 
4.5.2 X-ray crystallographic studies with Rv1155 and Rv2991 
 
 Five X-ray datasets were measured from yellow crystals of the Rv1155-
F420 complex, which diffracted X-rays from 1.9 Å to 2.8 Å resolution. Each crystal 
structure was similar, but varied slightly in ways that provided details about the 
binding mode of F420 in Rv1155. For statistics on the datasets collected, please 
refer to Appendix A. All Rv1155-F420 crystals were in the space group P212121 
and had unit cell dimensions of a = 54.04 Å, b = 65.76 Å, c = 76.59 Å, while 
Rv1155 apoenzyme crystallised in the space group P21 and had unit cell 
dimensions a = 46.95 Å, b = 55.12 Å, c = 55.23 Å. The strongest electron density 
for F420 was observed in the lowest resolution dataset. There is clear electron 
density in each structure to guide the unambiguous placement of two glutamate 
residues, the phosphate, the lactyl moiety, and the ribityl moiety of F420. The 
additional three to four glutamate residues of the F420 polyglutamate chain are 
likely unstructured in the solvent channels of the crystal. The negative charges of 
the phosphate group and the polyglutamate tail of F420 are accommodated by a 
tunnel of positively-charged residues in Rv1155 (Figures 4.8 and 4.9), an 
interaction which anchors the coenzyme to the protein.  
 Just adjacent to the ring system binding site is a large, unoccupied and 
uncharged cleft (Figure 4.9), which may be the binding site of potential 
substrates. Crystal structures of F420 binding proteins, and of other flavoproteins 
in which the flavin directly engages in redox chemistry with the substrate, indicate 
that any potential substrate must be in close physical proximity to the ring 
system. In F420-binding proteins, hydride transfer is achieved via transfer from the 
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central carbon of the ring system. Therefore, substrates must bind near the ring 
system in order to facilitate redox reactions.  
 Although there is conclusive evidence for the placement of the coenzyme 
in the protein, the five crystal structures obtained are all ambiguous about the 
face of the ring system, that is, whether the pyrimidine portion of the 
deazaolloxazine is positioned away from or toward Lys 57. However, the F420 
electron density in the 2.8 Å resolution dataset provides evidence for the vector 
of the deazaisoalloxazine ring (Figure 4.8). In this dataset, density extending 
beyond the ribityl moiety to the central nitrogen of the ring system is observed. 
This vector for the deazaisoalloxazine ring system places it close to the predicted 
substrate binding site, which likely requires a hinge motion of 1-2 Å to facilitate 
enzymatic catalysis.  
 
Figure 4.8. Crystal structure of Rv1155 bound to F420 at 2.8 Å resolution. Rv1155 is a homodimer 
with one molecule of F420 bound. Residues marked with apostrophe belong to chain B (cyan) and 
unmarked residues belong to chain A (grey). Electron density for F420 is contoured at 1.0σ level. 
The image was rendered using molecular graphics software CCP4mg125.  
Y77 
K57’ 
H138 
H27’ 
R63’  
R59’  
N60’ 
Y79 
Y140 
Q32’  
R55’ 
I51’ S50’ 
K26’ 
Chapter 4!
 
 61 
 The same sample that was used to obtain Rv1155-F420 crystals was also 
analysed by nESI-MS, as previously discussed (Figure 4.7 B). The mass 
spectrum indicates that several species of Rv1155-F420, although the 
predominant complex in the mixture is Rv1155 bound to two molecules of F420-6. 
However, only one F420 molecule per dimer is observed in the crystal structure. It 
may be that the concentration of F420 (1:1 molar ratio of Rv1155 to F420) was not 
sufficient to populate all the binding sites (please refer to Chapter 6 for details on 
protein purification). Another explanation is that the apoenzyme Rv1155 crystal 
formed in the drop and F420 subsequently soaked into the crystal. This 
interpretation is supported by the observation that unstructured glutamates after 
the first two residues in the polyglutamate chain of F420 interact with the 
unoccupied polyglutamate binding site of a symmetry-related Rv1155 
homodimer. The strong electron density (σ = 1) for one glutamate residue in the 
F420 binding site of the symmetry related molecule indicates that the unstructured 
glutamates of F420 bound in one unit cell may be preventing the binding of a 
second F420. 
Tryptophan 77 of Rv1155 may be involved in positioning the 
deazaisoalloxazine ring system of F420. Molecular dynamics simulations predicted 
that Trp 77 would engage in a π-stacking interaction with the ring system; 
however, the structure shown here does not support this model. Nonetheless, the 
variation in electron density for Trp 77 among all datasets collected may provide 
some insight into the role of this residue at the active site. In the unoccupied 
active site, Trp 77 (chain B) is disordered in all datasets. In the F420-occupied 
active site, there is clear electron density for Trp 77. This observation suggests 
that the presence of F420 orders Trp 77. 
Missing electron density due to disorder in the crystal at key, 
biochemically-relevant regions of these molecules makes it difficult to understand 
the active site of this enzyme with a high level of mechanistic detail. Further co-
crystallization experiments may produce a more useful crystal form for this 
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protein. However, these structures provide strong evidence for the F420 binding 
site on this protein and a starting point for identifying the substrate binding site. 
 
 
Figure 4.9. Electrostatic potential surface representation of F420 binding site in Rv1155. Positively 
charged residues (at neutral pH) accommodate the phosphate and polyglutamate of F420. The 
proposed substrate binding site is adjacent to the deazaisoalloxazine ring system of F420. Molecular 
graphics representation of the molecule was rendered using CCP4mg125.  
 
 Co-crystallisation screens with Rv2991-F420 did not produce diffraction-
quality crystals of the complex. These screens are described in Chapter 6 of this 
thesis. However, crystals of apoenzyme Rv2991 could be reproduced with known 
crystallisation conditions (Pedro Alzari et al., unpublished results). This indicates 
that the isolated protein is properly folded and suitable for crystallisation trials. 
Soaking experiments and co-crystallisation trials are currently underway to obtain 
the F420-bound Rv2991 structure. 
 A structural superimposition of Rv2991, Rv1155, and F420-dependent Ddn 
reveals that they share a high degree global fold similarity (Figure 4.10) even 
though the sequence identity of these three enzymes is only around 20%. Ddn 
oligomerises into a pentamer, while Rv2991 and Rv1155 are dimers. The 
architecture of the small domain for Ddn is markedly different than that of either 
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Rv2991 or Rv1155 These observations suggest that Rv2991 and Rv1155 should 
be in a class of F420-binding proteins distinct from Ddn, an observation which is 
supported by studies of homologues in M. smegmatis175 and by computational 
analyses171.  
 
 
Figure 4.10. Structural alignment of Ddn-F420, Rv1155-F420, and Rv2991. The alignment was 
performed using the MultiProt Server (http://bioinfo3d.cs.tau.ac.il/MultiProt/) with Ddn174 (grey, PDB 
ID: 3R5W), Rv1155-F420 (magenta), and Rv2991 (blue, PDB ID: 1RFE). C-alpha RMSD of Rv2991 
and Ddn is 1.51 and of Rv1155 and Ddn is 1.28. The C-alpha RMSD of Rv2991 and Rv1155 is 
1.45. (Number of residues: Rv1155, 141; Rv2991, 151; Ddn 109). 
 
4.6 Trial enzymatic reactions with Rv1155 and Rv2991 
4.6.1 Rv1155 and Rv2991 do not exhibit PNPOx activity  
 
 To determine if either Rv1155 or Rv2991 are capable of PNPOx activity, 
as is Rv2607 (Chapter 3), each enzyme was incubated with PNP, PMP, and PLP 
in the presence of F420 or F420H2 (Figure 4.11 A-C) and the reaction was followed 
by UV/Vis spectroscopy. The substrate, PNP, the product, PLP, and coenzyme, 
F420, have absorbance maxima at 325 nm, 388 nm, and 420 nm respectively at 
pH 7.5. Oxidation of PNP and its depletion results in a decrease in absorbance at 
325 nm, an increase in absorbance at 388nm with the formation of the product 
PLP, and a decrease in the absorbance at 420 nm indicating the reduction of 
protomer, 180° 
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F420. No spectral changes were observed in the presence of untagged Rv1155 or 
Rv2991 that had been thawed from frozen storage or freshly purified. Clarified 
lysate from bacteria overexpressing Rv1155-GST or His6x-Rv2991 was also 
tested for activity to determine if Rv1155 requires another protein or small 
molecule endogenous in E. coli for PNPOx activity. The clarified lysate did not 
result in spectral changes consistent with PNPOx enzymatic activity. The results 
indicate that Rv1155 and Rv2991 likely do not function as a PNPOxs. Unlike 
Ddn, Rv1155 and Rv2991 cannot metabolise prodrug PA-824 (Figure 4.11 D). 
However, because these are negative results, it is difficult to conclusively rule out 
other factors for inactivity, such as the requirement of a small molecule or partner 
protein from Mtb.  
  
4.6.2 Rv1155 and Rv2991 do not recognize aflatoxin as a substrate 
 
Mycobacterium smegmatis homologues of enzymes in the DDN and PNPOx 
families have been linked to F420 metabolism with transposon mutagenesis 
studies designed to identify enzymes in M. smegmatis responsible for the 
degradation of aflatoxin, a food crop mycotoxin175,167. Of the five M. smegmatis 
isolates that did not degrade aflatoxin, four insertions disrupted the fbiC gene, 
which encodes the enzyme that catalyses the last step of the biosynthesis of FO, 
the deazaflavin precursor to F420. 
 One isolate disrupted the gene that encodes FGD. The enzymes 
responsible for this activity were identified by fractionating protein extracts, 
testing for aflatoxin degredation, and identifying active enzymes with proteomic 
tools. Five enzymes belonging to the DDN family and four enzymes in the 
PNPOx family were expressed recombinantly, purified, and shown to catalyse 
the F420-dependent reduction of aflatoxins and analogues containing the 
coumarin core175.  
 Rv1155 and Rv2991 were tested for activity with coumarin analogues 
(Figure 4.11 E-H) by monitoring spectroscopic changes, as described above. No 
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spectral changes were observed in the presence of any of the coumarin 
compounds, nor did any of these compounds bind by STD NMR (Figure 4.11 
E-H). 
 
 
Figure 4.11. Test enzymatic reactions conducted with Rv1155 and Rv2991. The following 
substrates were screened for activity with Rv1155 and Rv2991 separately in the presence of either 
F420 or F420H2: (A) pyridoxine 5’-phosphate, (B) pyridoxamine 5’-phosphate, (C) pyridoxal 5’-
phosphate, (D) PA-824, (E) coumarin, (F) 7-hydroxycoumarin, (G) 7-hydroxy-4-methylcoumarin, 
and (H) imperatorin.  
 
 These results are maybe not surprising as aflatoxin and coumarin 
analogues are unlikely natural substrates for these mycobacterial enzymes, as 
neither Mtb and its close relative, M. smegmatis, would normally encounter these 
toxins in their natural environment.  
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4.7 Conclusions 
 
 Rv1155 and Rv2991 were previously annotated in the Mtb genome as 
probable FMN-binding PNPOx-like proteins with unknown function. The 
biophysical and structural results described here suggest that they are not FMN-
dependent PNPOxs, as is Rv2607, but are instead members of a novel F420-
dependent class of proteins that share a global fold similarity. The trial enzymatic 
reactions conducted with Rv1155 and Rv2991 rule out any obvious function 
these enzymes may posses. The catalytic activities of Rv1155 and in particular, 
Rv2991, are further explored in Chapter 5.  
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Chapter 5 
Design, development, and screening of a targeted 
flavoprotein fragment library 
 
5.1 Background  
 
Functional genome annotation is usually achieved by employing computational 
methods to infer evolutionary relationships between protein sequences176. While 
this information can guide initial hypotheses of protein function, protein 
characterisation via biochemical methods remains essential to definitive gene 
annotation. This is especially important in light of the widespread misannotation 
of genes177 and the abundance of gene products with homologues of unknown 
function, also known as “conserved hypothetical” proteins (CHPs)178. CHPs are 
proteins encoded in the genomes of organisms from multiple phylogenetic 
lineages, none of which have been functionally characterised179. Any newly 
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sequenced bacterial genome contains about 30-40% genes encoding CHPs180. 
As discussed in Chapter 1, Section 1.3, the Mtb genome includes over a 
thousand CHPs19. Partial or inaccurate gene function information poses serious 
challenges to the study of this human pathogen and can impede the discovery of 
novel drug targets.  
 Few gene products in Mtb, and even fewer CHPs, have been assigned 
function based on experimental data. One major reason for this is the paucity of 
experimental techniques to elucidate the function of CHPs. Knock-out or knock-
down mutation studies181, transcriptional profiling182, and more recently, 
metabolomics technologies183 are some existing experimental approaches to 
studying protein function. While these techniques can provide evidence of CHP 
function, they tend to be technically challenging and low-throughput. 
5.2 Objective and rationale 
 
The objective of this thesis work is to explore the applicability of fragment-based 
methods to protein function prediction. Fragment-based approaches, as 
described in Chapter 1, Section 1.2.2.2, involve the use of sensitive biophysical 
techniques to detect relatively weak non-covalent binding interactions between a 
target protein and low molecular weight compounds (<300 Da) known as 
‘fragments’. As described previously, these fragments are typically elaborated 
with the guidance of protein structural information into inhibitors with greater 
complexity and affinity for the target101. The advantage of biophysical screening 
over traditional approaches to function prediction is that it does not require time-
consuming genetic experiments. Further, a priori protein structure information is 
an advantage, but is not necessary to conduct the screen. This work provides the 
first example, to our knowledge, of the application of fragment-approaches to 
investigate the natural substrates of CHPs. This will be referred to herein as the 
‘fragment-to-substrate’ approach. 
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5.3. Methodological approach 
 
Because fragments tend to interact with a target macromolecule weakly, 
fragment screening must be conducted using sensitive biophysical techniques. 
Proteins of unknown function have been previously studied with biophysical 
screening methods, DSF184, SPR185, and MS186. There are several examples of in 
silico structure-based function prediction approaches, which are predicated on 
screening potential substrates by docking them into a proposed active 
site187,188,189,190. As described in Chapter 1, ligand-binding screens can provide 
clues to protein function because they probe the molecular recognition properties 
of the target.  
 
5.3.1 Fragments as chemical tools 
 
Fragments may be useful chemical tools to investigate substrate specificity. 
Although fragments tend to be weak binders by virtue of their limited size and 
chemical complexity, they are known to have high ligand efficiency (ΔG/number 
of non-hydrogen atoms)191. Fragments of a natural substrate can recapitulate the 
binding properties of the parent substrate192,102,193. Early studies showed that 
fragments derived from substrates of beta-hydroxy-betamethylglutaryl coenzyme 
A reductase (and analogues) have additive free energies192. The total free energy 
of these fragments approximates the binding energy of the natural substrate, 
after correction for the linking energy. Other work demonstrated that the 
fragmented substrates of thymidylate synthase can bind the active site in a 
similar fashion to analogous moieties of the original substrate102. It has been 
reported that fragments of NADPH binding to E. coli ketopantoate reductase103 
can identify the ‘hot spots’ of the binding site, which contribute most to the 
binding energy of the cofactor. These studies retrospectively analyse the binding 
of a known substrate by determining the free energy contribution and binding 
mode of the substrate’s constituent fragments. This thesis work aims to 
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determine if the prospective case is also true, i.e., whether fragments binding to a 
target enzyme can predict substrates for that enzyme. 
 Central to the success of this approach is a fragment library that is 
reflective of the chemical space occupied by natural substrates, which is 
markedly different from that of drug molecules. For example, natural products 
tend to have a greater prevalence of features such as chirality194. Some 
commercial providers have developed fragment libraries for drug design inspired 
by natural ligands, including BioFragments developed by Asinex 
(http://www.asinex.com/BioFragments.html) and Fragments of LifeTM from 
Emerald Biosciences195 (http://www.emeraldbiostructures.com/services/ 
fragmentscreening/). There has also been recent interest in developing 
metabolite-like fragment libraries in academic laboratories, with particular 
emphasis on introducing fragments with more sp3 centres196,197. Fragment 
libraries targeted to specific classes of proteins have also been created198, 
perhaps most notably for kinases199. These targeted and metabolite-like fragment 
libraries have been designed to broaden the chemical space sampled by 
fragments used to design inhibitors. 
 The goal of this work is to develop a biologically-relevant, targeted 
fragment library that can probe the substrate specificity of enzymes in Mtb. This 
fragment library was assembled based on natural substrates of proteins 
functionally related to the target enzyme. The Protein Databank (PDB) was a 
source of natural ligand information. Using a computational technique called 
‘virtual fragment linking’ (VFL)200, statistical models were created based on 
binding fragments, which were used to predict likely substrates from a database 
of known metabolites in the cell. Figure 5.1 summarises this ‘fragment-to-
substrate’ workflow.  
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Figure 5.1. A schematic describing the ‘fragment-to-substrate’ workflow. The protein targets 
selected for this study are known flavoproteins; therefore, the ligands of flavin (FMN, FAD, and 
F420)-dependent proteins were selected from the PDB (1500 ligands). Molecules such as salts, 
gases, metals, and inhibitor compounds were excluded. The remaining ligands were compared to 
low molecular weight (<300 Da) compounds with good aqueous solubility (>1 mM) in the ZINC 
database201 (http://zinc.docking.org/) using Tversky200 similarity scores. Commercially-available 
fragments within the desired size and solubility ranges were manually selected to construct a 
fragment library that is representative of diverse chemical scaffolds. The library was screened 
against the target proteins using STD NMR. Fragments that bind to the target were analysed by 
VFL and compared to all known metabolites in the Mtb cell from the Kyoto Encyclopedia of Genes 
and Genomes (KEGG) database202 (approximately 4000 molecules). From the top ranking VFL 
hits, 80 molecules were manually selected as potential substrates and a subset were tested for 
enzymatic activity.  
 
5.4 F420-dependent enzymes Rv1155 and Rv2991 as model CHPs 
 
As described in Chapter 2, Rv2991 and Rv1155 are annotated as PNPOx-like 
proteins with unknown function. The work presented in this thesis demonstrates 
that these two enzymes do not exhibit PNPOx activity (Chapter 4, Figure 4.11), 
nor do they have affinity for predicted cofactor FMN (Chapter 4, Figure 4.4). 
Rv2991 and Rv1155 both bind strongly to the mycobacterial redox coenzyme 
F420.  These two mycobacterial proteins will be used as model systems because 
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they are members of the same structural class of enzymes and each have no 
known function. Perhaps the most well-studied F420-dependent system in Mtb is 
an enzyme called Ddn, which is responsible for activating a pro-drug PA-824 
currently in clinical trials for TB25,147 (see Chapter 4 for a description of the 
mechanism of action). As novel F420-dependent enzymes in Mtb, Rv2991 and 
Rv1155 are interesting targets. 
 A structural superimposition of Rv2991 and Rv1155 (Figure 5.2) reveals 
that they share similar global fold topology with an RMSD = 1.45 Å (number of 
residues: Rv2991, 153; Rv1155, 141). Although these enzymes share global fold 
similarity, they have relatively low sequence identity (33%). A region with high 
sequence identity between the two proteins is the polyglutamate binding site, 
which is consistent with the observation that these proteins both bind F420 (Figure 
5.2, conserved residues are shown in surface representative, dark blue). The 
dimer interface is another region of high sequence similarity between these two 
proteins. However, the predicted active sites of Rv2991 and Rv1155 are each 
comprised of non-conserved residues (Figure 5.2, white residues and inset 
images). These observations suggest that Rv1155 and Rv2991 could bind 
different classes of ligands and may be functionally divergent enzymes within an 
evolutionarily-related class. The structural similarities and differences of Rv1155 
and Rv2991 make them interesting model systems for exploring the applicability 
of fragments to probe the substrate specificity of related enzymes. 
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Figure 5.2. Structural comparison of F420-dependent Rv1155 and Rv2991. Rv1155 (yellow) with 
bound F420 (C atoms) overlaid with Rv2991 (grey) (PDB ID: 1RFE). Residues with surface 
representation are colored according to sequence similarity between Rv2991 and Rv1155. Dark 
blue residues are conserved, light blue residues have a conserved residue type, and white residues 
are not conserved. The small domain adjacent to the F420 ring system (the predicted substrate 
binding site) is comprised of residues that are not conserved. The Rv1155-F420 and Rv2991 active 
site are shown in the inset images. F420 is present in the Rv1155 structure only. The image was 
generated using CCP4mg125.  
 
5.5 Library design and development 
 
A fragment library to target F420-dependent Rv1155 and Rv2991 was designed 
based on known natural ligands bound to flavoproteins deposited in the PDB. 
The ligands of FMN-, FAD-, or F420-dependent proteins in the PDB were 
selected, which led to a set of 810 compounds. This set was further filtered 
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based on molecular weight (>5 heavy atoms), solubility (>500 µM in water), and 
by excluding compounds containing inorganic atoms. Protein precipitants and 
crystal cryoprotectants were removed with a custom Pipeline Pilot203 structure 
filter and drug molecules were manually excluded. The filtering process retained 
350 molecules, which comprise a diverse dataset of natural ligands to known 
flavoproteins. This work was done in collaboration with Dr. Andreas Bender and 
Sean Hudson (Department of Chemistry, University of Cambridge). 
 This set of query molecules was employed for similarity searching in the 
ChemBridge, ChemDev, Ryan Scientific, Enamine, Life Chemical, ChemDiv, and 
Specs libraries obtained from the ZINC201 database and filtered based on 
molecular weight and solubility (<300 Da and >1 mM). ECFP4 fingerprints were 
employed as descriptors, which belong to the class of circular fingerprints that 
were shown to capture structure-bioactivity relationships rather well in previous 
studies204,. The similarity coefficient chosen was the Tversky coefficient205 as 
implemented in PipelinePilot (due to the assumption that fragments represent 
substructures of the ligands from the PDB set). The Tversky coefficient is 
calculated as shown in the equation below. 
 ! !"#$%&' !,! = !! ∗ ! + !! ∗ ! + !! 
 
Here, ‘A’ refers to a library compound while ‘B’ refers to a natural flavoprotein 
ligand from the query dataset derived from the PDB. The variable a describes the 
number of molecular features only in A (and not in B), while b describes 
molecular features only in B (and not in A). The variable c is the number of 
features in common between A!and B200. The weighting factors were set to α%= 1 
and β%= 0 in order to bias the selection of fragments towards those that are as 
much a complete substructure of the query compounds as possible, while 
omitting those parts of the experimental ligands that are not captured by the 
fragment from the calculation, given that a fragment is meant to represent only a 
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part of the high-affinity binder. A complete list of all fragments in the target library 
can be found in Appendix B.  
5.6 Fragment screen of Rv1155 and Rv2991 
 
Rv2991 and Rv1155 were each screened against the flavoprotein fragment 
library in the presence and absence of F420 first by DSF and then by STD NMR. 
These techniques are described in Chapter 1. A fragment-only control screen 
revealed that 13% (9/70) of the fragments in the library are not assayable by DSF 
using SYPRO® Orange dye system due to the intrinsic fluorescence of these 
compounds.  
 For Rv2991-F420, 46% (28/61) of fragments in the library increased the Tm 
by least twice the standard deviation of the DMSO control (0.4). Please refer to 
Appendix C, Table C1 for full results. Among the fragments that did not increase 
the Tm of the protein, 15% (9/61) decreased the Tm of the protein by more than 
1 °C, 38% (23/61) of fragments had no effect on the Tm, slightly increased it, or 
slightly lowered it (± <1 °C), and 1 fragment produced a complex, multi-transition 
melt curve. Screening the same fragment library against Rv1155-F420 revealed 
that only 15% (9/61) of fragments increased the Tm by least twice the standard 
deviation of the DMSO control (0.6). The Tm of Rv1155 was significantly lowered 
(>1 °C) in the presence of 38% (23/61) of fragments. There was little change in 
the Tm of Rv1155 with 46% (28/61) of fragments (± <1 °C), and 1 fragment 
produced an uninterpretable melt curve. Because most fragments either 
increased or did not significantly decrease the Tm of Rv1155 or Rv2991, all 70 
fragments were analysed for binding by STD NMR. 
  A screen of the flavoprotein library against Rv2991 by STD NMR 
revealed fragment hits in the presence and absence of F420 with a hit rate of 17% 
(12/70) (Figure 5.3). Complete NMR spectra for all fragment hits against Rv2991 
can be found in Appendix C. Binding was observed only in the presence of F420 
for 25% of the binding fragments (Figure 5.3 C). For fragments that showed 
binding by STD in both presence and the absence of F420, enhanced binding 
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signal was observed when F420 was present in the reaction mixture (Figure 5.2 
A). Thermal unfolding studies with Rv2991 indicate that the Rv2991-F420 complex 
is significantly stabilised relative to the apoenzyme (Chapter 4, Figure 4.4), which 
may increase the amount of functional protein available to engage in a binding 
event. For some fragments, the π-stacking interaction between the 
deazaisoalloxazine ring system of F420 and the fragment may be required for the 
fragments to bind. For all fragments screened, no STD signal was observed in 
the presence of F420 and fragment only. 
 
Figure 5.3. STD NMR fragment hits for Rv2991. (A) Example STD NMR spectra for Rv2991 with 
fragment E-B4. Where it is present, the reaction components exist in the following concentrations: 
Rv2991 (25 µM), fragment (1 mM), F420 (50 µM). One dimensional 1H NMR spectrum of aromatic 
proton resonances (purple); STD NMR spectrum of reaction mixture containing Rv2991, F420, and 
fragment E-B4 (green); STD NMR spectrum of reaction mixture containing Rv2991 and fragment 
E-B4 (red); STD NMR spectrum of reaction mixture containing F420 and fragment E-B4 only (blue). 
Fragment E-B4 binds in both the presence and absence of F420, although the signal is stronger in 
the presence of F420. (B) Fragments binding to Rv2991 in both the presence and absence of F420. 
(C) Fragments binding to Rv2991 in the presence but not in the absence of F420. The flavoprotein 
fragment library contains 70 fragments, which were all screened. 
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 There were significantly fewer clear STD NMR fragment hits for both apo- 
and holoenzyme Rv1155 (Figure 5.4) than there were for Rv2991. Only 2 
fragments from the targeted flavoprotein library were binding to Rv1155 by NMR 
(hit rate: 3%) and none of these showed binding to the protein in the absence of 
F420. The structural basis for this relatively lower hit rate is unclear. It may be that 
the chemical space occupied by the flavoprotein fragment library insufficiently 
samples potential Rv1155 binders. To expand the repertoire of fragments binding 
to Rv1155, a commercially-available fragment library containing 1249 fragments 
(Maybridge Fragment Libraries) was screened against Rv1155 by DSF (see 
Appendix C, Table C.2 for full results). Of the fragments in the library, 74 
increased the Tm beyond twice the standard deviation of the fragment-negative 
control. These 74 fragments were further screened by STD NMR and two 
additional ligand-observed NMR experiments, CPMG and WaterLOGSY 
(Appendix C, Figure C.3). This screening process yielded 9 fragment hits (Figure 
5.4 C) that share some structural similarities. The Maybridge library fragment hits 
against Rv1155 are specific to Rv1155; they do not bind Rv2991 as assessed by 
using DSF. Unlike Rv2991, no fragments have been discovered for Rv1155 that 
bind without F420. No binding signal is observed for these fragments in the 
absence of F420. Future structural studies with Rv1155 and Rv2991 will elucidate 
the basis of the differential selectivity observed between these two proteins. 
 A comparison of DSF and NMR results for Rv1155 and Rv2991 reveals 
that there is limited overlap in hits between the two techniques. For example, 
some fragments that had little effect on the Tm of the protein showed clear 
binding by NMR. Conversely, some fragments that seemed to increase the Tm 
were not hits by STD. This result is consistent with observations that orthogonal 
techniques for fragment screening do not always agree, particularly if DSF is 
used206,79. Each technique can identify unique hits206. Because ligand-observed 
NMR spectroscopy is a more established screening technique for fragments52, 
STD NMR fragments hits were prioritised. 
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Figure 5.4. STD NMR fragment hits for Rv1155. (A) Example STD NMR spectra for Rv1155 with 
fragment E-F10. Where present, reaction components exist in the following concentrations: Rv1155 
(25 µM), fragment (1 mM), F420 (50 µM). One dimensional 1H NMR spectrum of aromatic proton 
resonances (purple); STD NMR spectrum of reaction mixture containing Rv1155, F420, and 
fragment E-F10 (green); STD NMR spectrum of reaction mixture containing Rv1155 and fragment 
E-F10 (red); STD NMR spectrum of reaction mixture containing F420 and E-F10 only (blue). 
Fragment E-F10 does not bind in the absence of F420. (B) Fragment hits against Rv1155-F420 from 
flavoprotein fragment library (total number of fragments screened: 70). Fragment hits bind in the 
presence, but not the absence of F420. (C) Fragment hits against Rv1155-F420 from the Maybridge 
fragment library. Total number of fragments screened by STD NMR: 74 (fragments selected for 
screening by DSF). Fragment hits bind in the presence, but not the absence of F420. 
 
5.7 Virtual fragment linking results and preliminary enzyme assays 
 
VFL is a computational approach that analyses fragment screening data for a 
given target to predict molecules with greater affinity for that target200. It has been 
described as an in sillico method to ‘bridge the gap’ between low micromolar or 
millimolar fragments and nanomolar ligands. The technique is predicated on 
generating statistical models based on the chemical features, or ‘molecular 
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fingerprints’, of binding fragments. These models are then used to screen large 
libraries containing compounds that are more chemically complex than 
fragments. ‘VFL hits’ are predicted to bind the target with high affinity because 
they have a combination of molecular fingerprints highly represented in the set of 
binding fragments. The VFL approach has been used in the pharmaceutical 
industry to discover potent HTS hits based on fragment binding data. The 
schematic shown in Figure 5.5 illustrates the VFL approach using fragment and 
HTS data for the target nitric oxide synthase (iNOS). 
 
Figure 5.5. Schematic demonstrating the VFL approach. Fragments binding to iNOS (low 
micromolar binders) are analysed to determine statistically significant features in the set (middle). 
This information is used to create models that can predict nanomolar binders from an HTS library. 
The substructures highlighted in red are represented in the fragment set. Figure adapted from 
Crisman et al. J. Med. Chem. 2008200. 
 
VFL was used to create statistical models of the 12 metabolite-like fragments 
binding to Rv2991. In order to identify potential substrates for Rv2991, the 
models were compared to all small molecules found in Mtb cells. A curated 
library of Mtb metabolites does not currently exist for academic use. Therefore, a 
dataset of metabolites was compiled using substrates in the KEGG database202 
(http://www.genome.jp/kegg/), which included 3856 molecules. For the 12 
fragments binding to Rv2991 versus the 58 non-binding fragments, a Bayesian 
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model based on Molprint 2D fingerprint was generated207. The features 
differentiating the active and inactive datasets (74) were used to generate a 
second Bayesian model, which was used to screen the Mtb metabolome dataset. 
This work was done in collaboration with Dr. Andreas Bender (Department of 
Chemistry, University of Cambridge). Of the 120 top VFL hits, 80 were selected 
because they were small molecules involved in intermediary metabolism. The 
remaining 80 compounds were queried using KEGG Ligand SIMCOMP208 
(http://www.genome.jp/tools/simcomp/) to identify all known enzymatic reactions 
associated with each substrate. Six compounds out of the 80 were purchased as 
preliminary set of test substrates based on their predicted redox properties (see 
Chapter 6, Table 6.3).  
 A high-throughput spectrophotometric assay was developed to assess 
Rv2991 enzymatic activity. Because each test substrate has a unique 
spectrophotometric signature, the oxidation state of the cofactor was monitored. 
It reported that oxidised F420 can be detected sensitively with fluorescence 
spectroscopy209. In a pilot experiment, the test substrates were incubated with 
Rv2991 and the reduced form of the cofactor, F420H2. Reduced cofactor was 
generated enzymatically as reported previously169 using F420-dependent glucose 
6-phosphate dehydrogenase 1 (FGD-1), which oxidises glucose 6-phosphate 
(G6P) and thereby produces F420H2 (Figure 5.6 A; see Chapter 6, Figure 6.3 for 
the enzymatic reduction of F420). FGD-1 is removed from the reaction mixture 
prior to incubation with Rv2991. Of the 6 predicted substrates tested, one 
demonstrated Rv2991-dependent re-oxidation of F420H2 over time: 
5-methoxytryptamine (5-MT), an intermediate in tryptophan metabolism 
(Figure 5.6 B). Substrate, cofactor, and enzyme, concentration dependence of 
this activity was observed (Figure 5.6 C-F). Preliminary structure activity 
relationship (SAR) experiments indicate that only tryptamine (TP) also exhibits 
activity (Figure 5.6 B & G). Similar rates of F420H2 oxidation are observed when 
either 5-MT or TP are used as substrates. 
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Figure 5.6. Rv2991-F420H2 enzyme assay for predicted substrates. (A) Schematic representing the 
fluorescence-based assay to test the enzymatic activity of Rv2991 with test substrates predicted by 
VFL. (B) Active compounds 5-MT and TP, which show similar enzymatic profiles. (C) Time-
dependent oxidation of F420H2 in the presence of Rv2991 and 5-MT (blue trace). No activity is 
observed for control reactions without Rv2991 (green and purple traces), F420H2 (red and green 
traces), or 5-MT (cyan trace). Reaction components, where present, are at the following 
concentrations: Rv2991 (5 µM), F420H2 (50 µM), and 5-MT (1 mM). (D) 5-MT concentration 
dependence on the rate of F420 formation. (E) F420H2 concentration dependence on the rate of F420 
formation. (F) Rv2991 concentration dependence on the rate of F420 formation. (G) Inactive 
tryptamine analogues.  
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 The enzyme, cofactor, and substrate dependence on the rate of F420H2 
oxidation are promising indicators of enzymatic activity. The reaction appears to 
be dependent on Rv2991-F420, as no activity was observed when Rv1155 was 
used rather than Rv2991. Further, no change was observed when NADPH 
(λex: 340 nm λem: 450 nm)210 was used as an electron carrier, instead of F420H2. 
However, downstream experiments to validate and characterise this activity have 
been unsuccessful. The product of the reaction (with either 5-MT or TP as 
substrate) cannot be identified by LC-MS and 1D 1H NMR spectroscopy. Further, 
these methods show little decrease in the substrate signal over time. A major 
complicating factor is that the rate of the observed activity is very slow. Although 
the activity appears to be enzymatic based on the relevant controls, the kcat and 
KM of this reaction are 0.0033 s-1 and 1.5 mM, respectively, for 5-MT and 
0.0020 s-1 and 1.0 mM, respectively, for TP. This exceeding slow conversion rate 
requires high concentrations of enzyme and cofactor, which impose a number of 
technical challenges on LC-MS and NMR-based assays. Preliminary SAR 
studies (Figure 5.6 G, compounds 2-9) have failed to identify tryptamine 
analogues that exhibit a higher rate of enzymatic activity. These results provide 
interesting clues about the enzymatic properties of Rv2991, but the rate of the 
reaction is too slow to be considered biologically-relevant. Six of the 80 predicted 
VFL substrates have been tested for enzymatic activity. Additional VFL-predicted 
substrates must be screened to arrive at substrates that are turned over at faster 
rates. 
5.8 Conclusions and future work 
 
The work presented in this chapter demonstrates some foundational, proof-of-
concept studies to develop a ‘fragment-to-substrate’ method. A targeted fragment 
library for flavoproteins was designed and assembled. Biophysical techniques 
were employed to detect fragments binding to two structurally related F420-
binding proteins, Rv2991 and Rv1155, with unknown function. Fragments bound 
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to each protein, but fewer fragment hits were observed for Rv1155, as compared 
to Rv2991. A high hit rate for Rv2991 was observed (17%) against the 
flavoprotein fragment library. Bayesian models were created based on the hits 
against Rv2991, which were then used to screen all known metabolites in the 
Mtb cell. Among the VFL-predicted substrates tested, two demonstrated 
enzymatic activity via a fluorescence-based assay that monitors the redox state 
of the cofactor. This enzymatic activity, however, falls short of rates that are 
expected from natural substrates. However, this procedure will be used in future 
studies to screen additional predicted substrates for activity. 
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Chapter 6 
Experimental 
 
6.1 Protein overexpression and purification 
 
6.1.1 Purification of Rv2607 
 
The clone of Rv2607 was obtained as an amino-terminal 6x-histidine (His6x) tag 
fusion construct with a thrombin cleavage site in a modified pET28b vector from 
the laboratory of Dr. Thomas C. Terwilliger, Los Alamos National Laboratories, 
New Mexico, USA117. The construct also included a kanamycin resistance gene 
for selection. Rv2607 was transformed in E. coli BL21-Gold(DE3) cells 
(Stratagene). An overnight culture of a single colony grown at 37 °C with 
agitation was diluted 1:100 into 500 mL Luria Broth (LB) supplemented with 40 
µg/mL kanamycin. The culture was incubated at 37 °C with shaking. Protein 
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expression was induced when the culture reached an OD600nm of 0.6 with the 
addition of isopropyl thiogalactopyranoside (IPTG) to a final concentration of 
1 mM. The culture was further incubated at 20 °C for 20 hrs with agitation. Cells 
were harvested by centrifugation (14000 xg, 15 min). The bright yellow cell pellet 
was resuspended in 20 mM Tris-HCl, pH 8.0, 100 mM NaCl. The cells underwent 
one freeze-thaw cycle (-80 oC) and were further lysed by sonication (Misonix S-
4000, amplitude 60%, 1 s on, 1 s off for 30 s, repeated 3 times). The cell lysate 
was centrifuged (48,000 xg, 30 min) and the clarified yellow supernatant was 
applied to a Ni-NTA affinity column (5 mL) pre-equilibrated with buffer A (20 mM 
Tris-HCl, pH 8.0, 100 mM NaCl, 20 mM imidazole). The column was washed with 
equilibration buffer (150 mL) until the flow through no longer contained any 
protein, as determined by a Bradford test136. The protein was eluted with elution 
buffer (20 mM Tris-HCl, 500 mM NaCl, 300 mM imidazole, pH 8.0). The eluted 
protein was buffer exchanged into phosphate buffered saline (PBS), pH 7.6, 
containing 10% glycerol and 1 mM β-mercaptoethanol (β-ME) using 10 kDa 
molecular weight cut off centrifugal filters (Millipore). SDS-PAGE analysis 
showed that the protein was purified to >95% homogeneity and the yield of the 
purified protein was determined to be 140 mg per 1 L of cells with the Bradford 
assay. 
 
6.1.2 Purification of Rv1155 and Rv2991 
 
The expression clone of Rv1155 was obtained as an aminoterminal His6x-MBP 
fusion construct with TEV cleavage site from Dr. Yves Bourne (Architecture et 
Fonction des Macromolécules Biologiques, CNRS, Marseille, France)118  and the 
clone of Rv2991 was obtained as an aminoterminal His6x fusion construct with 
TEV cleavage site from the laboratory of Prof. Pedro Alzari (Institut Pasteur, 
Paris, France). Rv1155 and Rv2991 were each transformed in E. coli BL21(DE3) 
cells. An overnight culture of a single colony from each transformation was 
diluted 1:100 into LB (2 L) supplemented with 100 µg/mL ampicillin. The cultures 
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were incubated with shaking at 37 oC. Protein expression was induced when the 
cultures reached an OD600nm of 0.4-0.6 with the addition of IPTG to a final 
concentration of 1 mM.  The cultures were further incubated at 25 oC for 16 hrs 
with agitation. The cells were then harvested by centrifugation and were 
resuspended in equilibration buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
10 mM imidazole) and subjected to sonication on ice. The lysate was cleared by 
centrifugation (50 min, 10000 xg) and the supernatant was loaded onto HiTrap 
HP nickel affinity column 5 mL (GE Healthcare) pre-equilibrated with equilibration 
buffer. The column was washed with equilibration buffer (20x column volume). 
The target proteins were eluted with elution buffer (50 mM Tris-HCl, pH 7.5, 
150 mM NaCl, 300 mM imidazole). His6x-MBP-Rv1155 and His6x-Rv2991 protein 
were buffer exchanged into a buffer optimized for the TEV protease cleavage 
reaction (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 1 mM DTT) 
using 10 KDa centrifugation filters (Millipore). The tags were cleaved from each 
fusion by incubating TEV protease with Rv1155 and Rv2991 at 1:100 molar ratio 
each at 25 oC for 2 hrs. The TEV and any uncleaved protein were removed by 
loading the reaction mixture onto a second HiTrap HP nickel affinity column with 
a 50 mL superloop (GE Healthcare). The eluate was retained and any uncleaved 
Rv1155 or Rv2991 bound on the resin electrostatically was removed with high 
salt buffer (50 mM Tris-HCl, pH 7.5, 600 mM NaCl, 10 mM imidazole). The eluted 
protein was pooled and purified by SEC with a 16/60 Superdex-75 column (GE 
Healthcare) pre-equilibrated with 50 mM postassium phosphate buffer, pH 7.5, 
100 mM NaCl for Rv1155 and 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 20 mM 
dithioretriol (DTT) for Rv2991. Fractions eluted from column were analysed by 
SDS-PAGE. Fractions containing pure Rv1155 or Rv2991 (corresponding to a 
molecular weight of ~16 kDa and ~18 kDa, respectively) were pooled and 
concentrated with 10 kDa cutoff centrifugation filters (Millipore). The protein 
concentration was determined by Abs280 with the calculated extinction coefficient 
based on the untagged sequence, 18450 cm-1 M-1 for Rv1155 and 27960 cm-1 M-1 
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for Rv2991. The yield was determined to be 10 mg per L of cells for Rv1155 and 
14 mg per 1 L of cells for Rv2991. 
 
6.2 Biophysical characterisation of Rv2607, Rv1155, and Rv2991 by MS 
 
6.2.1 Confirmation of molecular weight  
 
The calculated and observed MW of Rv2607, Rv1155, and Rv2991 can be found 
in the Table 6.1. The calculated molecular weight was based the translated DNA 
sequencing results. All samples were prepared for MS by desalting with C18 Zip 
Tip® (Millipore) pipette tips according to the manufacturer’s specifications and 
eluted in a solution of acetonitrile and 0.05% trifluoroacetic acid (TFA). The 
samples were analysed by electrospray ionisation positive ion mode with a Q 
Star Elite Mass Spectrometer (Applied Biosystems/MDS Sciex).  
 
6.2.2 MS analysis of oligomerisation state and cofactor stoichiometry 
 
A Synapt HDMS system optimised for the transmission of non-covalent 
complexes was used to record nESI-MS spectra211. All samples were prepared in 
100 mM ammonium acetate. Rv2607 (20 µM) was analysed with co-purified FMN 
(no exogenous FMN was added). Rv2991 (12 µM) incubated with F420 prior to 
analysis (1:5 molar ratio of enzyme:coenzyme). Rv1155 (10 µM) was prepared 
as described in Section 6.6. Each protein sample (2.5 µL) was electrosprayed 
from gold-coated glass capillaries212. To preserve the non-covalent interactions 
between the protein and cofactor, the MS parameters used for the Synapt were: 
capillary voltage, 1.7 kV; sample cone, 80-100 V; trap and transfer collision 
energy, 15 V and 12 V respectively; backing pressure 3.8 mbar; trap and IMS 
pressure 5e−2 and 5e−1 mbar, respectively; time-of-flight analyser pressure 
1.16e−6 mbar. For the Rv2607 collision-induced dissociation (CID) experiment, 
the ‘trap and transfer collision energies’ were 150 V and 110 V respectively to 
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affect dissociation. Data were processed with MassLynx 4.0 software 
(Waters/Micromass).  
 
Protein Calculated MW (Da) Observed MW (Da) Comments 
Rv2607 27493.8  27438.0 The experimental value is 
consistent with the molecular 
weight of the His6x-Rv2607 fusion 
protein (27493.8 Da), minus the 
aminoterminal methionine (-131 
Da), and with an added molecule of 
β-Me (+76 Da). 
 
Rv1155 16226.3 16227.0 The calculated molecular weight of 
Rv1155 is based on the WT 
sequence of Rv1155 (untagged) 
without the aminoterminal 
methionine (-131 Da) and with an 
added glycine (+74), which is 
retained from TEV cleavage. 
 
Rv2991 18032.4 18034.0 The calculated molecular weight of 
Rv2991 is based on the WT 
sequence of Rv1155 (untagged) 
without the aminoterminal 
methionine (-131 Da) and the 
carboxyterminal proline and with an 
added glycine (+74), which is 
retained from TEV cleavage. 
Table 6.1. Electrospray ionisation MS analysis Rv2607, Rv1155, and Rv2991 proteins used in the 
biophysical and enzymatic assays. The experimentally-observed MW of each protein is consistent 
with the calculated MW, which is derived from the expected protein sequence based on DNA 
sequencing data. 
 
6.2.3 Analysis of co-purified cofactor from Rv2607 
 
Extracted cofactor from Rv2607 and authentic FMN were analyzed with a Q Star 
Elite Mass Spectrometer (Applied Biosystems/MDS Sciex) by electrospray 
ionisation positive ion mode with a gold-plated nanospray tip. To extract the 
bound cofactor from Rv2607, a concentrated solution of purified Rv2607 
(270 µM) in 25 mM potassium phosphate buffer, pH 7.8, was heat-denatured for 
5 min at 100 oC. To the denatured protein was added 300 µL 25 mM potassium 
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phosphate buffer, pH 7.8, and the mixture was filtered using a 10 K molecular 
weight cutoff Vivaspin 500 centrifugation filter (15 min at 17,900 xg). The flow 
through was desalted with C18 Zip Tip® pipette tips (Millipore) previously 
washed with acetonitrile and equilibrated with 0.1% TFA in ultrapure water. The 
analyte was eluted in a solution of acetonitrile and 0.05% TFA. The FMN 
standard sample was prepared by acidifying it in 0.1% TFA to a final 
concentration of 500 µM. All spectra were calibrated internally using a solution of 
cesium iodide (100 mg/mL).  
 
6.3 Enzymatic characterisation of Rv2607 
 
6.3.1 Synthesis of PNP 
 
PNP was synthesised based on a published procedure213 with some 
modifications. Under argon atmosphere, freshly prepared 0.5 M NaOH (3.2 mL) 
was added to PLP (200 mg, 0.8 mmol). The solution was deoxygenated by 
bubbling with argon for 5 min at room temperature (25 °C), after which sodium 
borohydride (12 mg, 0.32 mmol) was added portionwise with stirring. The 
reaction was stirred until complete as judged by TLC (SiO2, 80:20 methanol:ethyl 
acetate v:v). The reaction was quenched with acetone (120 µL, 1.6 mmol) and 
allowed to stir at 25 °C for 30 min, after which NaOH (147 mg, 3.7 mmol) was 
added. After stirring for another 15 min at 25 °C, the reaction mixture was loaded 
directly onto a column containing 5 mL Amberlite IRA-743 (5 mL in a 1.0 x 11.0 
cm column) to remove borate salts. The resin had been conditioned by washing 
with absolute ethanol (25 mL), water (3 x 25 mL), 1 M HCl (25 mL), water (25 
mL), 1 M NaOH (25 mL), and finally equilibrated with water (50 mL). The flow 
through was collected and the resin was washed with enough water (5-7 mL) so 
that PNP could no longer be detected spectrophotometrically (λmax = 325 nm at 
pH 7.5)214. The flow-through and wash were pooled and this solution was further 
purified with weakly acidic cation exchange resin Amberlite IRC-76 (10 mL in a 
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1.30 x 12.5 cm column). The resin had been conditioned with 1 M NaOH 
(50 mL), water (50 mL), 1 M HCl (50 mL), and finally equilibrated with water 
(100 mL). The flow through was collected and pooled with two elution steps: 0.5 
M NaOH (5 mL) and water (10 mL). The resin was washed with water (10 mL) 
until PNP could not be detected spectrophotometrically. The eluted product was 
pooled, lyophilised, and resuspended in 100 mM potassium phosphate buffer, pH 
7.8. 1H NMR (D2O, 400 MHz): δ 7.77 (1H, s), 4.88 (2H, d, J = 6.9), 4.77 (2H, s), 
2.41 (3H, s). 
 
6.3.2 LC-MS assay for Rv2607-dependent PLP formation  
 
Proposed Rv2607 substrates, PNP and PMP, and the product, PLP, co-migrated 
by reverse-phase high-pressure liquid chromatography (HPLC). In order to 
resolve the product and substrates, an adduct was formed between PLP and 
DNPH. DNPH reactivity with PLP, PNP, and PMP was tested. To 1 mM solutions 
of PLP (100 µL), PNP (100 µL), and PMP (100 µL) in 25 mM potassium 
phosphate buffer (pH 7.8), a saturated solution of DNPH in 3 M HCl (10 µL) was 
added to a final concentration of 0.7 mM. As a negative control, 3 M HCl (10 µL) 
was substituted for DNPH. The PLP, PNP and PMP negative control reactions 
were carried out by substituting the substrate with 100 µL of 25 mM potassium 
phosphate buffer, pH 7.8. All reactions were carried out at 25 oC for 3 hrs. 
 Reaction mixtures (150 µL each) containing 1 mM PNP or 1 mM PMP, 
10 µM FMN, and 10 µM Rv2607 in 25 mM potassium phosphate buffer were 
incubated at 25 oC for 3 hrs. Enzyme, cofactor, and substrate negative control 
reactions were treated in a similar manner. After 3 hrs incubation at 25 oC, the 
reaction was quenched with addition of 10 µl of DNPH in 3 M HCl to a final 
concentration of 0.7 mM. The reaction mixture was filtered with 10 kDa MW 
cutoff centrifugation filters and 10 µl of the reaction was analyzed by LC-MS. 
 Analysis of the enzymatic reactions and controls were performed on 
Agilent 1100 LC-MS instrument using Luna (3 µm) C18 column (50 x 2 mm, 
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Phenomenex). Solution A contained water and 0.1% formic acid. Solution B 
contained acetonitrile and 0.1% formic acid. The column was equilibrated with 
95% solution A for 1 min. The following gradient was used: 5% to 95% solution B 
from 1 to 11 min; 95% solution B from 11 to 15 min; 95% to 5% solution B from 
15 to 17 min; 5% solution B from 17 to 21.5 min. 
 
 
Figure 6.1. Reverse-phase HPLC analysis of control reactions between PLP, PNP, or PMP, and 
DNPH. HPLC chromatograms (270 nm) of reaction mixtures containing PLP and DNPH (i), PMP 
and DNPH (ii), PNP and DNPH (iii), DNPH (iv), PLP (v), PMP (vi), and PNP (vii). Reaction 
components, were at the following final concentrations: 1 mM PLP, PMP, PNP and 0.7 mM DNPH. 
All reactions were carried out in 25 mM potassium phosphate buffer, pH 7.8 at 25 oC for 3 hrs. The 
identity of each peak was assigned by electrospray ionisation in the positive ion mode (PLP-DNP 
m/z = 428). 
 
6.3.3 NMR time-course assay of Rv2607-dependent PLP formation 
 
The enzymatic reaction was monitored by 1H NMR spectroscopy using a Bruker 
Avance 700 MHz spectrometer with a TXI cryoprobe. The reaction mixture 
contained 1 mM PNP, 10% deuterium oxide, and 20 µM 2,2,3,3-D4-3-
(trimethylsilyl)propionic acid (TSP-d4) as an internal standard in 25 mM 
potassium phosphate buffer, pH 7.6. The reaction was initiated with the addition 
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of enzyme to a final concentration of 28 µM or an equivalent volume of buffer for 
the control. The enzymatic reaction and enzyme negative control (200 µL) were 
added to 3 mm capillary tubes (Bruker), which were maintained at constant 
temperature (25 °C). The spectrometer conditions were optimised with the 
enzyme negative control sample. The sample was locked, shimmed, and the 
pulses were calibrated for water suppression using excitation sculpting with 
gradients215. At selected time points, 1H NMR spectra were collected for 18 hrs. 
Each experiment consisted of 4 dummy scans followed by 8 collected scans, 
resulting in 63 s of acquisition time per data point. Chemical shifts are reported in 
ppm relative to TSP (δ = 0 ppm). The spectra were processed and analysed 
using TopSpinTM 1.8 (Bruker, MA, USA). Substrate conversion was determined 
by comparing integrals of the C2-1H signals associated with PLP (7.80 ppm) to 
that of PNP (7.75 ppm). To confirm the identity of the product formed, the 
reaction mixture was enriched with authentic PLP after 18 hrs.  
 
6.3.4 Steady state kinetic characterisation of Rv2607 
 
The rate of product formation was monitored spectrophotometrically with a 
Varian Cary 400 UV/Vis spectrophotometer 1 cm pathlength quartz cuvettes 
(Varian). The product, PLP, has a λmax at 388 nm and 4900 cm-1M-1 is the 
extinction coefficient for that wavelength214. The rate of PLP production was 
measured for various concentrations of PNP: 50 µM, 100 µM, 175 µM, 250 µM, 
500 µM, 750 µM, 1000 µM, 1500 µM. No exogenous FMN was added. All 
solutions were made in 100 mM potassium phosphate buffer, pH 7.8. The KM and 
kcat for Rv2607 were determined by fitting the initial rate (less than 10% 
conversion) of product formation as a function of substrate concentration to the 
Michaelis-Menten equation by non-linear regression using GraphPad Prism 5 
(GraphPad Software, Inc., La Jolla, California, USA). 
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6.4 Test enzymatic reactions with Rv1155 and Rv2991 
 
All activity assays were conducted using Varian Cary 300 Bio UV/Vis 
Spectrophotometer in 1 cm pathlength quartz cuvettes (Varian). Where present, 
the reagents were at the following concentrations: 1 µM enzyme (Rv1155 or 
Rv2991), 100 µM substrate (PNP, PMP, coumarin, 7-hydroxycoumarin, 7-
hydroxy-4-methylcoumarin, imperatorin, PA-824), 20 µM cofactor (F420 or FMN). 
Reaction mixtures (150 µl total) contained: 1) enzyme, substrate, and cofactor, 2) 
enzyme and substrate, 3) substrate and cofactor, 4) enzyme and cofactor. All 
reactions were carried out in 25 mM potassium phosphate buffer, pH 7.5. The 
reactions were initiated with the addition of enzyme and a wavelength scan (200-
500 nm) was collected every 2 min for 1 hr.  
 
6.5 Purification of F420 
 
6.5.1 Isolation and purification of F420 from M. smegmatis 
 
The protocol for F420 purification was developed by modifying existing 
procedures172,173. M. smegmatis cells were transformed with genes fbiA, fbiB, and 
fbiC, which were obtained in a pYUBDuet vector  from Prof. Edward N. Baker 
(University of Aukland, New Zealand). The genes fbiA, fbiB, and fbiC encode 
enzymes involved in the biosynthesis of F420216. It was confirmed that 
M. smegmatis cells transformed with the vector containing fbiABC have about 
five times higher F420 production levels than do the wild type (WT) cells (Figure 
6.2). The vector was electroporated into the M. smegmatis strain mc2155 as 
previously described173.  
 M. smegmatis cells overexpressing the F420 biosynthetic genes were 
grown in kilogram quantities in fermenters in LB broth. When the culture reached 
an OD600nm of 0.6, IPTG was added to a final concentration of 0.25 mM and 
further incubated for 2 days. For one round of purification, typically around 800 g 
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of M. smegmatis transformed with fbiABC was thawed at 4 °C and resuspended 
in a minimal volume of 25 mM potassium phosphate buffer, pH 7.5, being careful 
to avoid large clumps of cells (~1.6 L). The resuspension was autoclaved for 20 
min, cooled at 4 °C, and centrifuged at 40,000 xg for 50 min. The bright yellow 
supernatant was filtered with a 0.45 µm pore membrane filter (Millipore). The cell 
pellet was again resuspended in a minimal volume of 25 mM potassium 
phosphate buffer, pH 7.5 (~1 L) and the mixture was again autoclaved, 
centrifuged, and filtered as before.  
 
 
Figure 6.2. F420 concentration found in M. smegmatis cells transformed with FbiABC 
overexpression vector compared to WT. Transformants with either fbiABC or a control vector were 
cultured (5 mL) at 37 °C with shaking in the presence of kanamycin (50 µg/mL) until an OD600nm of 
0.6 was reached. An aliquot of each culture was removed and treated with IPTG (0.25 mM final 
concentration) and further incubated at 37 °C with shaking for 4 days. The cells were harvested by 
centrifugation and the wet cell pellets were weighed to normalise the fluorescence signal to the 
mass of the cell pellet. The cells were resuspended in 1 mL 100 mM potassium phosphate buffer 
pH 7.5, autoclaved for 20 min, centrifuged, and the supernatant was analysed by fluorescence 
spectroscopy (λex: 400 nm, λem: 470 nm). The concentration of F420 present was quantified with a 
calibration curve of a known standard of F420. Each sample was measured at 4 dilutions. There is 
approximately 5.5x greater F420 production in the +fbiABC strain in the presence of IPTG. 
 
 The supernatant from both autoclave cycles was pooled and loaded onto 
a quaternary aminoethyl ion exchange column equilibrated with 25 mM 
potassium phosphate buffer pH 7.5 buffer at flow rate of 0.5 mL/min at 4 °C. The 
column was then washed at a constant flow rate of 1 mL/min with 25 mM 
potassium phosphate buffer, pH 7.5, each containing increasing concentrations 
of NaCl. The eluate was monitored spectrophotometrically at λ = 420 nm (the 
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λmax of F420 at pH 7.5) and was collected in 500 mL fractions. Each eluted fraction 
was analysed by LC-MS. The column was first washed with 100 mM NaCl in 
potassium phosphate buffer (2 L). FO, a precursor to F420, was eluted with 250 
mM NaCl in potassium phosphate buffer (2 L). The column was further washed 
with 2.0 L 400 mM NaCl in potassium phosphate buffer. F420 eluted from the 
column with 2.0 L 600 mM NaCl potassium phosphate buffer. The presence of 
F420 species with 5 glutamates, F420-5 (m/z: 1160), and with 6 glutamates, F420-6 
(m/z: 1290) was detected by LC-MS. 
 The fractions containing F420 were removed from the high salt buffer using 
solid phase extraction (SPE) C18 cartridges according to the manufacturer’s 
protocol (Waters SEP-Pak Long). Conductivity measurements indicated that the 
SPE cartridges removed 97% of salts in the sample. The desalted F420 fractions 
were lyophilised, dissolved in a minimal volume of water.   
 The F420 was further purified by reverse-phase HPLC on a Varian Prep 
Star instrument using a Phenomenex Luna C18 (250 x 21.20 mm, 10 µm) 
column. Solution A was water and solution B was acetonitrile.  The column was 
equilibrated with 95% solution A and 5% solution B for 4 minutes. The following 
linear gradient was used: 95% to 80% solution A and 5% to 20% solution B from 
2 to 32 min, then 80% to 5% solution A and 20% to 95% solution B from 32 to 35 
min, and 5% solution A and 95% solution B for 5 min. The fractions containing 
F420 were pooled, lyophilised, and dissolved in a minimal volume of water. The 
concentration of F420 was determined with the extinction coefficient217 at 420 nm, 
which is 25.9 mM-1 cm-1. The product purity was assessed by LC-MS. Yield was 
determined to be 104 mg per 800 g M. smegmatis +fbiABC cells. 
 
6.5.2. Enzymatic reduction of F420 
 
Reduced F420 (F420H2) was prepared enzymatically using recombinant F420-
dependent glucose 6-phosphate dehydrogenase 1 (FGD-1) based on published 
protocols169,147. F420 was typically reduced at 50-250 µM concentrations with 
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FGD-1 and excess and glucose 6-phosphate (G6P) in 50 mM potassium 
phosphate buffer, pH 7.5 without exposure to light (total reaction volume 100-
500 µL). Before use, FGD-1 was removed from the reaction mixture by filtering 
with a 10 kDa cutoff centrifugation filter (Millipore).  
 
Figure 6.3. Enzymatic reduction of F420 by FGD-1. (A) Schematic representing FGD-dependent 
reduction of F420 in the presence of G6P. (B) UV/Vis scans (200-500 nm) of F420 reduction 
catalysed by FGD-1. The reaction mixture contained 100 µM F420, 6.25 mM G6P, and FGD-1 and 
was monitored for 1 hr with a scan taken every min. (C) Time-dependent change in select 
wavelength of F420 in the presence of FGD-1 and G6P. A decrease in the absorbance at 420 nm 
and 400 nm and concurrent increase in the absorbance at 325 nm is observed as F420H2 is formed. 
 
6.6 Protein crystallography 
 
Rv1155 and Rv2991 were prepared for crystallographic screens by 
overexpressing, isolating, and cleaving the His6x-MBP-Rv1155 and His6x-Rv2991 
as described in section 6.1.2. For crystallographic studies with Rv1155, after the 
second nickel affinity column to remove TEV and any tagged protein, the protein 
was incubated with F420 (1:1 ratio) at 4 °C overnight. The protein was then 
purified by SEC with Superdex 75 10/300 GL (GE Healthcare), pre-equilibrated 
with 10 mM Tris-HCl, pH 7.5, 150 mM NaCl. Prior to injecting the protein, the 
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equilibration buffer containing 25 µM F420 (15 mL) was loaded onto the column. 
The eluate was monitored at two wavelengths (λF420 = 420 nm, λ F420, protein = 280 
nm) and collected in 1 mL fractions (refer to Figure 6.4 for a chromatogram of 
Rv1155 co-purified with F420 by SEC).  
 
 
Figure 6.4. Chromatogram and SDS-PAGE analysis of Rv1155-F420 co-purification by SEC. (A) 
Chromatogram of Rv1155 co-eluting with F420. Wavelengths monitored are 420 nm (red) and 
280 nm (blue). (B) SDS-PAGE analysis of purified fractions. F420 begins to elute at 15 mL (peak 1). 
A small contaminant protein elutes from the column (peak 2), which corresponds to fractions 1 and 
2 in panel B. Peak 3 is the co-migrating complex of Rv1155 and F420 (fractions 3–7 in panel B), as 
the absorbance at 280 nm is enhanced by the presence of F420. Excess F420 is eluted from the 
column at ~30 mL. The SDS-PAGE (9–13) shows the absence of protein in these fractions. 
 
 The peak corresponding to the co-elution of Rv1155 and F420 (peak 3) 
was pooled, concentrated to 500 µM, and used to screen commercially-available 
crystallisation conditions (384 in total) at a ratio of 1:1 protein to screening 
condition by sitting drop vapor diffusion (Crystal Phoenix, Art Robbins 
Instruments LLC, CA, USA). A number of conditions produced crystal hits, which 
are summarised in Table 6.2.  
 As discussed in Chapter 4, Section 4.4.2, crystals obtained for the 
Rv1155-F420 complex had only one molecule of F420 bound, even though there 
are two coenzyme binding sites in the Rv1155 homodimer and nESI-MS analysis 
indicates that it predominantly binds two molecules of F420. The purification 
procedure described above produces Rv1155-F420 at about 1:1 molar ratio of 
enzyme to coenzyme. Future studies will be directed towards optimising the 
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conditions shown in Table 6.2 and screening for new crystallisation conditions for 
Rv1155-F420, where F420 is added in molar excess of Rv1155. 
 
Condition Example Crystal image 
0.1 M MES pH 6.5, 25% PEG 3000 
 
0.1 M MES pH 6.5, 25% PEG 4000 
 
0.1 M MES pH 6.5, 25% PEG 6000 
 
 
0.1 M MES pH 6.5, 25% PEG 8000 
 
 
0.2M NaF, 20% PEG 3350 
 
 
0.2M KF, 20% PEG 3350 
 
0.2M sodium formate, 20% PEG 3350 
 
 
0.2M Potassium formate, 20% PEG 3350 
 
 
Table 6.2. Crystallographic conditions that produced crystals for Rv1155-F420. All conditions were 
identified in a 96 well commercial crystallographic screen, PEGs Suite (Qiagen). Images were 
taken by Rock Imager 500 (Formulatrix, Inc, Waltham, MA, USA). 
 
 Co-crystallisation studies with Rv2991 and F420 have been unsuccessful 
in producing diffraction-quality crystals of the enzyme-coenzyme complex. 
However, apoenzyme crystals of Rv2991 could be reproduced based on known 
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crystallisation conditions (Alzari, P. et al., unpublished results), which 
demonstrates that the protein is properly folded and is suitable for crystallisation 
trials. Figure 6.5 shows example Rv2991 apoenzyme crystals, which formed in 
the presence of 100 mM TRIS-HCl, pH 8.5, 200 mM sodium acetate, 20% PEG-
4000, and 10 mM MgCl2. Optimisation of the protein to mother liquor ratio 
dramatically affects the morphology of the crystals. A ratio of 1:1 or 1:2 protein to 
crystallisation condition yields thin needles that appear after 1 day (Figure 6.5 A). 
Larger needles were observed with 2:1 ratio of protein to mother liquor. Long 
three-dimensional crystals were obtained with a ratio of 1:3 protein to 
crystallisation condition in the drop (Figure 6.5 B), which appear after about 3 
weeks.  
 
Figure 6.5. Optimisation of apoenzyme Rv2991 crystals. (A) Rv2991 apoenzyme crystals obtained 
from hanging drops at a ratio of 1:1 protein to mother liquor in the drop. (B) Rv2991 apoenzyme 
crystals obtained from hanging drops at 1:3 protein to mother liquor in the drop. Crystallisation 
condition: 100 mM TRIS-HCl, pH 8.5, 200 mM sodium acetate, 20% PEG-4000, and 10 mM MgCl2. 
 
6.7 Isothermal titration calorimetry 
 
Untagged Rv1155 and Rv2991 were prepared as described in 6.1.2 and 
underwent dialysis overnight at 4 °C with stirring in 600 mL 100 mM potassium 
phosphate buffer, pH 7.4, 20 mM NaCl with 10 KDa MW cutoff Slide-A-Lyzer 
dialysis cassette (ThermoScientific, MA, USA). For Rv2991, 5 mM DTT was 
added to the dialysis buffer. F420 was dialysed into the same buffer In general 
using 500 Da MW cutoff Float-A-Lyzer dialysis cassette (Spectrum Laboratories, 
 

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Inc, CA, USA). The dialysate was retained to rinse the instrument before use. For 
the Rv1155-F420 titration, 10 µM Rv1155 and 275 µM were used and for the 
Rv2991-F420 titration, 51.3 µM Rv2991 and 1.15 mM F420. 
 All titrations were performed on a MicroCal iTC200 calorimeter (GE 
Healthcare). In general, experimental parameters were set as follows: 17 1.5 µL 
injections (0.5 µL for first injection) with 3 s duration (1 s for the first injection), 
5-7 µcal/s reference power, 4 s filter period, and 100-180 s spacing. Data was 
analysed and figures were generated using Origin (OriginLab Corp, MA, USA). 
 
6.8 Optimisation of DSF experiments  
 
Optimal conditions for DSF experiments with Rv1155 and Rv2991 were 
determined by varying buffer type (potassium phosphate buffer and TRIS-HCl), 
pH (7.0-8.5), ionic strength (0-350 mM NaCl), protein concentration (1 µM-
10-µM), and SYPRO® Orange dye concentration (1x-90x). Because high 
baseline fluorescence signal was observed in the Rv2991 melt curve, a number 
of additives were also tested, such as 1-15% DMSO, 1-15% dioxane, and 1-
30 mM DTT. The conditions that produced the optimal melt curve for Rv1155 
were 100 mM Tris-HCl, pH 8.0, 100 mM NaCl, 2.5x SYPRO® Orange dye 
concentration, and 5 µM protein. An interpretable melt curve was obtained for 
Rv2991 under the following conditions: 20 mM potassium phosphate buffer, 
pH 7.5, 20 mM NaCl, 1x SYPRO® Orange dye, 5 µM protein, and 20 mM DTT. 
All samples (100 µL total volume) were tested in triplicate and incubated over a 
temperature range of 37-90 °C with a ramp rate of 0.01 °C/s, collecting a scan 
every 1 s. The data was analysed using Protein Thermal Shift v1.0 (Applied 
Biosciences, CA, USA). The Tm was determined by calculating the negative 
derivative of the melt curve and identifying the local minima77. 
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6.9 Fragment library design, development, and screening 
 
6.9.1 Fragment library design 
 
The targeted fragment library was designed based on ligands of known 
flavoprotein (FMN-, FAD-, and F420-binding). Ligands from each of the targeted 
classes were obtained from the PDB (http://www.rcsb.org/pdb). Ions, gases, 
buffer additives, metal complexes were excluded from the flavoprotein ligands. 
The filtering process retained 1500 substrates. Commercially-available fragment-
like molecules were created by compiling the ChemBridge, ChemDiv, Enamine, 
Life Chemicals, Ryan Scientific and Specs supplier databases from the ZINC 
repository (http://zinc.docking.org/, Bioinfomatics and Chemical Informatics 
Research Center, University of California San Francisco, CA, USA) and filtering 
by predicted solubility in water >1 mM and MW <300 Da using Pipeline Pilot v6.1 
(Accelrys, CA, USA). The commercial fragments that represented substructures 
of the ligands were identified by calculating Tversky coefficients in Pipeline Pilot 
using the extended connectivity molecular fingerprint (ECFP4) generated for 
each molecule. Representative fragments (70) were ordered to create the 
focused flavoprotein library. 
 
6.9.2 Fragment library construction 
 
Approximately 10 mg quantities of each fragment were weighed using an 
analytical balance and deposited in removable glass vials that are stored in a 96 
well plate holder with an air-tight seal. Enough DMSO-d6 was added to the 
fragment to yield a solution of 100 mM final concentration. The solution was 
pipetted up and down repeatedly to mix. The plate was covered and stored at 
25 °C overnight. The following morning, the plates were stored at -80 °C. As a 
quality control measure, a 1D 1H NMR spectra of each fragment in buffer was 
obtained. 
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6.9.3 NMR screen of fragment library 
 
Reaction mixtures (200 µL) contained 1 mM fragment with and without 25 µM 
Rv2991 or 25 µM Rv1155 were prepared in 50 mM Tris-HCl buffer at pH 7.5, 50 
mM NaCl, 10% (v/v) D2O, 20 µM deuterated TSP-d4 and 2.5% (v/v) DMSO-d6. All 
fragments were screened in the presence and absence of 50 µM F420. The 
samples were then pipetted into 3-mm NMR capillaries (Bruker) and placed in 5 
mm NMR tubes (Wilmad-LabGlass, NJ, USA). STD and WaterLOGSY 1D 1H 
NMR spectra were acquired at 278 K on a Bruker DRX 700 MHz NMR 
spectrometer (Bruker, MA, USA) equipped with a 5 mm triple resonance inverse 
(TXI) cryoprobe with z-gradients. STD experiments employed a 40 ms selective 
Gaussian 180° pulse at a frequency alternating between ‘on-resonance’ (0.9 
ppm) and ‘off-resonance’ (40 ppm) after every scan. WaterLOGSY experiments 
employed a 40 ms selective Gaussian 180° shaped pulse at the water signal 
frequency and a NOE mixing time of 1 s. Water signal suppression was achieved 
using a W5 Watergate gradient spin-echo pulse sequence. The spectra were 
processed using TopSpin 3.0 software (Bruker UK, Coventry, UK) and 
WaterLOGSY spectra were scaled relative to the TSP-d4 peak intensity at 0 ppm. 
 
6.9.4. DSF screen of fragment library 
 
Samples (100 µL total volume) were prepared in optical 96-well reaction plates 
(Applied Biosystems, CA, USA), each containing 5 mM fragment, 5 µM Rv2991, 
2.5x SYPRO® Orange (Invitrogen, OR, USA), in the presence or absence of 50 
µM F420. Fluorescence data were collected on 7500 Real Time PCR with 
instrument software v2.0.6 (Applied Biosciences, CA, USA) using the ROX filter 
(λex: 587 nm, λem: 607 nm). The data was analysed using Protein Thermal 
Shift v1.0 (Applied Biosciences, CA, USA). The Tm was determined by calculating 
the negative derivative of the melt curve and identifying the local minima77. 
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6.10 Rv2991 substrate prediction 
 
6.10.1. Virtual fragment linking 
 
In order to generate a dataset of putative metabolites, the Mtb H37Rv 
metabolome was derived from the KEGG database202, comprising a total of 3,856 
endogenous metabolites with valid structural entries. For the 12 binding 
fragments, a Bayesian model based on Molprint 2D fingerprint was generated207 
using circular fingerprints with a radius of 2. The 74 features possessing highest 
information gain between the binding fragments and non-binding fragments were 
used to generate a Bayesian model, which was used to screen the Mtb 
metabolome dataset. The 120 endogenous metabolites scoring highest in the 
model were subject to human inspection. This approach is analogous to previous 
'Virtual Fragment Linking' efforts, where it could be shown that information about 
fragment binding can be joined to retrieve small molecules with high bioactivity 
from a molecular database200. 
 
6.10.2 Test enzymatic assays with Rv2991 
 
Test enzymatic reactions (100 µL total volume) contained Rv2991 (5 µM), F420H2 
(50 µM), 1 mM test substrate dissolved in DMSO (1% DMSO). Enzyme, 
coenzyme, and substrate negative control reactions were prepared by adding an 
equivalent volume of buffer or DMSO in the place of the reagent. The preliminary 
set of test substrates are shown in Table 6.3. Samples were prepared in 100 mM 
potassium phosphate buffer, pH 7.4, 50 mM NaCl. F420 was reduced 
enzymatically as described in Section 6.5.2 using FGD-1, which was removed by 
10 kDa MW cutoff filtration before it was added to the reaction mixture. All 
reaction mixtures were monitored by fluorescence spectroscopy (λex = 400 nm, 
λem = 470 nm) to detect the formation of oxidised F420.  
Chapter 6     !
 
 104 
 
Table 6.3. Select VFL hits that were tested for enzymatic activity with Rv2991 and F420H2. These 
potential substrates were selected because they participated in known reduction-oxidation 
reactions, as documented by KEGG database. 
 
 One substrate, 5-methoxytryptamine (5-MT), demonstrated time-
dependent re-oxidation of F420 in the presence of enzyme, substrate, and 
coenzyme, but not in the absence of any reagent components (named compound 
ES-1 in Table 6.3). To confirm that this change is enzymatic, a range of 
concentrations of substrate (1000-15.6 µM), enzyme (5-0.5 µM), and coenzyme 
Compound ID Structure and name Metabolic pathway Example reduction-oxidation reaction 
ES-1  
 
 
 
 
 
5-methoxytryptamine 
Tryptophan metabolism 
 
Melatonin degredation 
Tryptamine+++Oxygen+++NADPH+!+
+N5Hydroxyl5tryptamine+++H2O+++NADP+ 
ES-2  
 
 
 
 
 
 
Indolepyruvate 
Tryptophan metabolism 
 
Indolepyruvate + NADH + H+ ! 
Indolelactate + NAD+ 
ES-3  
 
 
 
 
 
Xanthine 
Purine metabolism Xanthine + NADH + H+ ! 
Hypoxanthine + NAD+ H2O+ 
ES-4  
 
 
 
 
 
 
 
N65(delta25Isopentenyl)5
adenosine 
Biosynthesis of 
secondary metabolites  
 
Zeatin biosynthesis 
N6-(delta2-Isopentenyl)-adenosine 5'-
monophosphate + Reduced flavoprotein + Oxygen 
! trans-Zeatin riboside  monophosphate + 
Oxidized flavoprotein + H2O+ 
 
ES-5  
 
 
 
 
 
Catharanthine 
Indole alkaloid 
biosynthesis  
 
Biosynthesis of 
secondary metabolites 
 
Geissoschizine + NADP+ !  
4,21-Dehydrogeissoschizine + NADPH 
ES-6  
 
 
 
3-Hydroxyphenylacetate  
Tyrosine+metabolism++
 
3-Hydroxyphenylacetate + Oxygen + NADPH + H+ 
! Homogentisate + NADP+ + H2O+ 
 
O
H
N
NH2
H
N
O OH
OH
N
H
NN
N
H
HN
N
H
NO
O
N
H
N
O
HN
N
H
O
HO
O
OH
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(250-7.8 µM) were tested. Analogues of 5-MT were tested for activity as 
described above. KM and kcat for the 5-MT and TP reactions were determined by 
fitting the initial as a function of substrate concentration to the Michaelis-Menten 
equation by non-linear regression using GraphPad Prism 5 (GraphPad Software, 
Inc., La Jolla, California, USA). 
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Appendix A 
Crystallographic refinement statistics 
Data Collection DS1 DS2 DS3 
    
X-ray source Grenoble Grenoble Grenoble 
Resolution limit (Å) 30-2.0 (2.07-2.00)* 30-2.6 (2.69-2.60) 30-1.9 (1.97-1.90) 
Space group P212121 P212121 P212121 
Unit cell dimensions (Å) 55.3, 66.5, 77.0 54.5, 66.2, 76.8 54.5, 66.2, 76.8 
Completeness (%) 94.7 (99.9)  99.9 (100.0) 99.8 (99.8) 
<I/σ(I)> 26.97 (6.13) 40.08 (15.07) 25.00 (5.98) 
Wilson B-factor (Å2) 18.55 48.37 25.64 
    
Refinement statistics    
Resolution limits (Å) 30-2.00(2.07-2.00) 30-2.6 (2.69-2.60) 30-1.9 (1.97-1.90) 
Number of reflections in working set 17238 (1780) 8209 (793) 20694 (2033) 
Number of reflections in test set 1469 (162) 746 (65) 1772 (166) 
Rwork (%) 25.0 (26.0) 24.1 (32.0) 21.8 (27.9) 
Rfree (%) 29.0 (31.0) 29.9 (43.0) 24.8 (28.6) 
Number of atoms:    
Protein; solvent; ligand/ion 2122; 89; 39 2103; 0; 0 2156; 148; 72 
    
Geometry r.m.s deviations:    
Bond lengths (Å) 0.006 0.007 0.006 
Bond angle (o) 1.62 1.40 1.34 
 
Table A.1. Crystallographic refinement statistics for Rv1155-F420 datasets 1-3. Highest resolution 
shell is shown in parenthesis. Rmerge, multiplicity of measurements, and mosaicity are not shown, 
as unmerged reflections and diffraction images are no longer available. All datasets contain F420. 
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Data Collection DS4 DS5 
   
X-ray source Grenoble Grenoble 
Resolution limit (Å) 40-2.4 (2.49-2.40) 35-2.8 (2.90-2.80) 
Space group P212121 P212121 
Unit cell dimensions (Å) 55.3, 66.5, 76.9 54.0, 66.8, 76.6 
Completeness (%) 99.5 (100.0) 100.0 (100.0) 
<I/σ(I)> 38.20 (14.44) 31.42 (6.80) 
Wilson B-factor (Å2) 36.95 66.34 
   
Refinement statistics   
Resolution limits (Å) 40-2.4 (2.49-2.40) 35-2.8 (2.90-2.80) 
Number of reflections in working set 10567 (1027) 6498 (623) 
Number of reflections in test set 923 (90) 612 (66) 
Rwork (%) 21.8 (28.5) 20.9 (32.2) 
Rfree (%) 28.4 (42.7) 27.4 (40.1) 
Number of atoms:   
Protein; solvent; ligand/ion 2144; 45; 47 2148; 12; 54 
   
Geometry r.m.s deviations:   
Bond lengths (Å) 0.007 0.007 
Bond angle (o) 1.30 1.35 
 
Table A.2. Crystallographic refinement statistics for Rv1155-F420 datasets 4-5. Highest resolution 
shell is shown in parenthesis. Rmerge, multiplicity of measurements, and mosaicity are not shown, 
as unmerged reflections and diffraction images are no longer available. All datasets contain F420. 
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Appendix B 
Targeted enzyme fragment library  
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O=C1C=CC(C2=CC=CC=C21)=O 
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Appendix C 
Fragment screening data 
 
 
Table C.1. Melting temperatures of Rv2991 and Rv1155 in the presence of fragments from the 
targeted flavoenzyme library. 
ΔTm$Rv2991$ ΔTm$Rv1155$
Fragment) *)F420) +)F420) *)F420) +)F420)
E,A1$ ,1.2$ ,0.7$ 0.2$ 2.0$
E,A2$ ,2.7$ 0.1$ 0.5$ 0.3$
E,A3$ ,1.8$ 2.2$ 0.8$ ,1.5$
E,A4$ ,1.5$ ,0.4$ 1.1$ ,1.5$
E,A5$ N/A$ N/A$ N/A$ N/A$
E,A6$ ,0.9$ ,0.1$ 0.2$ ,0.7$
E,A7$ ,0.6$ ,0.4$ 0.8$ 1.3$
E,A8$ N/A$ N/A$ N/A$ N/A$
E,A9$ N/A$ N/A$ N/A$ N/A$
E,A10$ ,0.3$ ,0.4$ ,0.4$ ,2.2$
E,A11$ ,1.2$ ,1.3$ ,1.3$ ,1.9$
E,A12$ ,2.7$ 0.7$ 1.4$ ,1.7$
E,B1$ 0.0$ ,0.1$ ,0.4$ ,1.5$
E,B2$ ,0.6$ ,0.4$ 1.1$ ,0.2$
E,B3$ ,1.8$ 1.6$ 1.9$ ,0.7$
E,B4$ ,0.3$ 0.4$ ,0.1$ ,1.0$
E,B5$ ,4.5$ ,29.6$ 0.8$ 4.0$
E,B6$ 1.7$ ,0.4$ 1.4$ 0.0$
E,B7$ ,0.9$ 1.0$ 1.1$ ,0.7$
E,B8$ 0.3$ 0.7$ ,0.1$ 2.3$
E,B9$ ,0.9$ 0.4$ 0.2$ ,1.5$
E,B10$ ,0.6$ ,0.4$ ,0.1$ ,1.0$
E,B11$ ,0.3$ ,0.4$ ,0.7$ ,1.5$
E,B12$ 1.1$ ,1.9$ ,2.2$ ,1.5$
E,C1$ ,0.6$ ,0.1$ 0.8$ ,0.7$
E,C2$ ,0.6$ 1.3$ ,0.7$ ,0.5$
E,C3$ ,2.1$ 1.3$ 1.4$ ,0.7$
E,C4$ ,1.8$ 1.3$ 2.5$ ,1.5$
E,C5$ N/A$ N/A$ N/A$ N/A$
E,C6$ 0.0$ 0.1$ ,0.1$ ,3.7$
E,C7$ 0.3$ 0.1$ 0.5$ ,0.2$
E,C8$ N/A$ N/A$ N/A$ N/A$
E,C9$ ,17.2$ ,23.2$ ,12.6$ 1.5$
E,C10$ ,0.6$ 0.1$ 0.8$ ,0.2$
E,C11$ N/A$ N/A$ N/A$ N/A$
ΔTm$Rv2991$ ΔTm$Rv1155$
Fragment) *)F420) +)F420) *)F420) +)F420)
E,C12$ ,0.9$ ,0.1$ ,0.1$ ,0.2$
E,D1$ ,2.4$ 3.4$ 1.9$ ,1.2$
E,D2$ ,0.6$ 0.7$ ,0.1$ 0.5$
E,D3$ N/A$ N/A$ N/A$ N/A$
E,D4$ 0.0$ 0.7$ 0.8$ 2.5$
E,D5$ 0.6$ 0.7$ 0.5$ 0.8$
E,D6$ N/A$ N/A$ N/A$ N/A$
E,D7$ 0.3$ 0.1$ 0.5$ ,0.7$
E,D8$ ,1.8$ 0.4$ 0.2$ ,1.2$
E,D9$ ,1.8$ ,0.7$ 1.1$ ,0.7$
E,D10$ ,0.9$ ,0.4$ 1.1$ ,1.0$
E,D11$ N/A$ N/A$ N/A$ N/A$
E,D12$ ,2.7$ 0.7$ 1.4$ ,1.0$
E,E1$ ,1.2$ 0.4$ 1.1$ 0.0$
E,E2$ ,2.1$ 1.3$ 1.4$ ,1.7$
E,E3$ ,2.1$ 9.6$ 1.4$ 0.8$
E,E4$ ,0.9$ 1.3$ 1.4$ ,0.2$
E,E5$ ,0.6$ 1.0$ 1.4$ 0.3$
E,E6$ 0.3$ 0.4$ 1.7$ 0.5$
E,E7$ 0.3$ 0.4$ 1.4$ ,0.2$
E,E8$ ,0.9$ 1.0$ 1.4$ 1.3$
E,E9$ ,0.3$ 0.7$ 1.1$ 0.0$
E,E10$ ,6.3$ ,0.7$ 0.8$ ,1.7$
E,E11$ ,22.0$ ,26.1$ 0.8$ 0.0$
E,E12$ N/A$ ,29.1$ 0.2$ ,1.7$
E,F1$ ,0.3$ ,0.1$ ,0.1$ 0.5$
E,F2$ 0.3$ 0.1$ 0.2$ 0.3$
E,F3$ ,2.1$ ,28.8$ 2.8$ ,0.5$
E,F4$ N/A$ N/A$ N/A$ N/A$
E,F5$ 0.6$ 0.4$ 0.8$ ,0.2$
E,F6$ ,3.6$ ,1.9$ ,4.0$ ,3.4$
E,F7$ ,1.8$ 1.0$ ,0.4$ ,1.2$
E,F8$ ,0.6$ 0.4$ 0.8$ 0.0$
E,F9$ ,0.6$ 0.1$ 0.8$ 0.3$
E,F10$ ,2.2$ ,21.7$ 0.7$ ,1.0$
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Figure C.1. STD NMR spectra for fragment hits against Rv2991from the targeted flavoenzyme 
fragment library. 

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Figure C.2. STD NMR spectra for fragment hits against Rv1155 from the targeted flavoenzyme 
fragment library. The spectra are colour-coded as in Figure C2. 
 
 
Table C.2. Fragments from the Maybridge library that increase the Tm of Rv1155 by at least twice 
the standard deviation of the DMSO-only control on each screening plate. 
 
ID ΔTm 
MB022 0.5 
MB095 0.3 
MB031 1.9 
MB024 0.7 
MB027 0.8 
MB077 0.5 
MB143 0.3 
MB137 0.3 
MB176 0.3 
MB131 0.8 
MB179 0.3 
MB132 1.2 
MB199 1.7 
MB248 1.1 
MB202 0.2 
MB210 0.8 
MB211 0.2 
MB235 0.4 
MB237 0.6 
MB330 0.8 
MB288 2.1 
MB281 0.5 
MB320 0.5 
MB269 0.5 
MB299 0.8 
MB366 0.2 
MB343 0.7 
MB375 1.3 
MB383 3.1 
MB407 1.3 
MB392 0.6 
MB401 0.7 
MB362 0.4 
MB379 0.4 
MB432 0.8 
CA045 1.9 
CA212 0.8 
ID ΔTm 
AT0544 1.3 
AT1772 1.5 
AT0541 0.8 
CA206 0.6 
CA208 0.6 
CA010 0.8 
MB590 0.8 
MB600 1.2 
MB759 0.7 
MB775 0.7 
MB770 0.9 
MB880 0.5 
MB857 1.0 
MB875 1.2 
MB950 0.3 
MB911 2.0 
MB920 0.7 
MB937 0.7 
MB941 1.6 
MB992 0.8 
MB1078 0.3 
MB1135 1.1 
MB1120 0.3 
MB1081 0.3 
MB1121 0.3 
MB1145 1.1 
MB1146 0.5 
MB1159 0.7 
MB1201 1.4 
MB1154 0.7 
MB1164 2.3 
MB1238 0.9 
MB1270 0.9 
MB1298 0.9 
MB1276 0.7 
MB1335 0.5 
MB1313 0.5 
Appendix C     !
 
 121 
 
Figure C.3. STD NMR spectra for fragment hits against Rv1155 from the Maybridge library.
MB176 MB095 MB857 
MB407 MB024 MB132 
1D 1H 
Fragment 
WaterLOGSY  
Rv1155 + F420 + fragment 
STD  
Rv1155 + F420  + fragment 
STD  
F420 + fragment 
CPMG 
Rv1155 + F420 + fragment 
CPMG  
F420 + fragment 
WaterLOGSY 
F420 + fragment 
1D 1H 
Fragment 
WaterLOGSY  
Rv1155 + F420 + fragment 
STD  
Rv1155 + F420  + fragment 
STD  
F420 + fragment 
CPMG 
Rv1155 + F420 + fragment 
CPMG  
F420 + fragment 
WaterLOGSY 
F420 + fragment 
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